

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
16 January 2003 (16.01.2003)

PCT

(10) International Publication Number
WO 03/004487 A1

(51) International Patent Classification⁷: **C07D 401/04**,
401/14, 409/14, 417/14, 211/06, A61K 31/445, A61P
37/00, 11/06, 31/16

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZM, ZW.

(21) International Application Number: PCT/SE02/01311

(22) International Filing Date: 1 July 2002 (01.07.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0116179.3 2 July 2001 (02.07.2001) GB
0123037.4 25 September 2001 (25.09.2001) GB

(71) Applicant (for all designated States except US): **ASTRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **EVANS, Richard** [GB/GB]; AstraZeneca R & D Charnwood, Bakewell Road, Loughborough, Leicestershire LE11 5RH (GB). **PERRY, Matthew** [GB/GB]; AstraZeneca R & D Charnwood, Bakewell Road, Loughborough, Leicestershire LE11 5RH (GB). **SPRINGTHORPE, Brian** [GB/GB]; AstraZeneca R & D Charnwood, Bakewell Road, Loughborough, Leicestershire LE11 5RH (GB).

(74) Agent: **ASTRAZENECA AB**; Global Intellectual Property, S-151 85 Södertälje (SE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CII, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

(84) Designated States (regional): ARIPO patent (GII, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- of inventorship (Rule 4.17(iv)) for US only


Published:

- with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 03/004487 A1

(54) Title: PIPERIDINE DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY



(I)

optionally substituted heterocycl; R² is hydrogen or C₁₋₆alkyl; R³ is hydrogen or optionally substituted C₁₋₆alkyl; and R⁴ is alkyl, optionally substituted aryl, optionally substituted aralkyl or optionally substituted heterocycl; that are modulators of chemokine (especially CCR3) activity and are especially useful for treating asthma and/or rhinitis.

(57) Abstract: The invention provides a compound of formula (I), wherein: T is C(O) or S(O)₂; W is C(O) or S(O)₂; X is CH₂, O or NH; Y is CR⁵ or N; R¹ is optionally substituted aryl or

PIPERIDINE DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

The present invention concerns piperidine derivatives having pharmaceutical activity, to processes for preparing such derivatives, to pharmaceutical compositions comprising such derivatives and to the use of such derivatives as active therapeutic agents.

5 Pharmaceutically active piperidine derivatives are disclosed in WO99/38514, WO99/04794 and WO00/35877.

10 Chemokines are chemotactic cytokines that are released by a wide variety of cells to attract macrophages, T cells, eosinophils, basophils and neutrophils to sites of inflammation and also play a rôle in the maturation of cells of the immune system.

Chemokines play an important rôle in immune and inflammatory responses in various diseases and disorders, including asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. These small secreted molecules are a growing superfamily of 8-14 kDa proteins characterised by a conserved 15 four cysteine motif. The chemokine superfamily can be divided into two main groups exhibiting characteristic structural motifs, the Cys-X-Cys (C-X-C, or α) and Cys-Cys (C-C, or β) families. These are distinguished on the basis of a single amino acid insertion between the NH-proximal pair of cysteine residues and sequence similarity.

20 The C-X-C chemokines include several potent chemoattractants and activators of neutrophils such as interleukin-8 (IL-8) and neutrophil-activating peptide 2 (NAP-2).

The C-C chemokines include potent chemoattractants of monocytes and lymphocytes but not neutrophils such as human monocyte chemotactic proteins 1-3 (MCP-1, MCP-2 and MCP-3), RANTES (Regulated on Activation, Normal T Expressed and Secreted), eotaxin and the macrophage inflammatory proteins 1 α and 1 β (MIP-1 α and 25 MIP-1 β).


Studies have demonstrated that the actions of the chemokines are mediated by subfamilies of G protein-coupled receptors, among which are the receptors designated CCR1, CCR2, CCR2A, CCR2B, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10, CXCR1, CXCR2, CXCR3 and CXCR4. These receptors represent good targets 30 for drug development since agents which modulate these receptors would be useful in the treatment of disorders and diseases such as those mentioned above.

Histamine is a basic amine, 2-(4-imidazolyl)-ethylamine, and is formed from histidine by histidine decarboxylase. It is found in most tissues of the body, but is present

in high concentrations in the lung, skin and in the gastrointestinal tract. At the cellular level inflammatory cells such as mast cells and basophils store large amounts of histamine. It is recognised that the degranulation of mast cells and basophils and the subsequent release of histamine is a fundamental mechanism responsible for the clinical manifestation 5 of an allergic process. Histamine produces its actions by an effect on specific histamine G-protein coupled receptors, which are of three main types, H1, H2 and H3. Histamine H1 antagonists comprise the largest class of medications used in the treatment of patients with allergic disorders, especially rhinitis and urticaria. Antagonists of H1 are useful in controlling the allergic response by for example blocking the action of histamine on post-capillary venule smooth muscle, resulting in decreased vascular permeability, exudation 10 and oedema. The antagonists also produce blockade of the actions of histamine on the H1 receptors on c-type nociceptive nerve fibres, resulting in decreased itching and sneezing.

Viral infections are known to cause lung inflammation. It has been shown experimentally that the common cold increases mucosal output of eotaxin in the airways. 15 Instillation of eotaxin into the nose can mimic some of the signs and symptoms of a common cold. (See, Greiff L *et al* Allergy (1999) 54(11) 1204-8 [Experimental common cold increase mucosal output of eotaxin in atopic individuals] and Kawaguchi M *et al* Int. Arch. Allergy Immunol. (2000) 122 S1 44 [Expression of eotaxin by normal airway epithelial cells after virus A infection].)

20 The present invention provides a compound of formula (I):



wherein:

T is C(O) or S(O)₂;

W is C(O) or S(O)₂;

25 X is CH₂, O or NH;

Y is CR⁵ or N;

R¹ is optionally substituted aryl or optionally substituted heterocyclyl;

R² is hydrogen or C₁₋₆ alkyl;

R³ is hydrogen or optionally substituted C₁₋₆ alkyl;

30 R⁴ is alkyl, cycloalkyl, optionally substituted aryl, optionally substituted aralkyl or optionally substituted heterocyclyl;

- R^5 is hydrogen or C_{1-6} alkyl;
 wherein the foregoing aryl and heterocyclyl moieties are optionally substituted by:
 halogen, cyano, nitro, hydroxy, oxo, $S(O)_pR^{25}$, $OC(O)NR^6R^7$, NR^8R^9 , $NR^{10}C(O)R^{11}$,
 $NR^{12}C(O)NR^{13}R^{14}$, $S(O)_2NR^{15}R^{16}$, $NR^{17}S(O)_2R^{18}$, $C(O)NR^{19}R^{20}$, $C(O)R^{21}$, CO_2R^{22} ,
- 5 $NR^{23}CO_2R^{24}$, C_{1-6} alkyl, CF_3 , C_{1-6} alkoxy(C_{1-6})alkyl, C_{1-6} alkoxy, OCF_3 , C_{1-6} alkoxy(C_{1-6})alkoxy (preferably not forming an acetal), C_{1-6} alkylthio, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl (itself optionally substituted by C_{1-4} alkyl or oxo), methylenedioxy, difluoromethylenedioxy, phenyl, phenyl(C_{1-4})alkyl, phenoxy, phenylthio, phenyl(C_{1-4})alkoxy, heteroaryl, heteroaryl(C_{1-4})alkyl, heteroaryloxy or heteroaryl(C_{1-4})alkoxy;
- 10 wherein any of the immediately foregoing phenyl and heteroaryl moieties are optionally substituted with halogen, hydroxy, nitro, $S(O)_q(C_{1-4}$ alkyl), $S(O)_2NH_2$, cyano, C_{1-4} alkyl, C_{1-4} alkoxy, $C(O)NH_2$, $C(O)NH(C_{1-4}$ alkyl), CO_2H , $CO_2(C_{1-4}$ alkyl), $NHC(O)(C_{1-4}$ alkyl), $NHS(O)_2(C_{1-4}$ alkyl), $C(O)(C_{1-4}$ alkyl), CF_3 or OCF_3 ;
 p and q are, independently, 0, 1 or 2;
- 15 R^6 , R^7 , R^8 , R^9 , R^{10} , R^{11} , R^{12} , R^{13} , R^{14} , R^{15} , R^{16} , R^{17} , R^{19} , R^{20} , R^{21} , R^{22} , and R^{23} are, independently, hydrogen, C_{1-6} alkyl (optionally substituted by halogen, hydroxy or C_{3-10} cycloalkyl), $CH_2(C_{2-6}$ alkenyl), phenyl (itself optionally substituted by halogen, hydroxy, nitro, NH_2 , $NH(C_{1-4}$ alkyl), $N(C_{1-4}$ alkyl)₂, $S(O)_2(C_{1-4}$ alkyl), $S(O)_2NH_2$, $S(O)_2NH(C_{1-4}$ alkyl), $S(O)_2N(C_{1-4}$ alkyl)₂, cyano, C_{1-4} alkyl, C_{1-4} alkoxy, $C(O)NH_2$, $C(O)NH(C_{1-4}$ alkyl), CO_2H , $CO_2(C_{1-4}$ alkyl), $NHC(O)(C_{1-4}$ alkyl), $NHS(O)_2(C_{1-4}$ alkyl), $C(O)(C_{1-4}$ alkyl), CF_3 or OCF_3) or heterocyclyl (itself optionally substituted by halogen, hydroxy, nitro, NH_2 , $NH(C_{1-4}$ alkyl), $N(C_{1-4}$ alkyl)₂, $S(O)_2(C_{1-4}$ alkyl), $S(O)_2NH_2$, $S(O)_2NH(C_{1-4}$ alkyl), $S(O)_2N(C_{1-4}$ alkyl)₂, cyano, C_{1-4} alkyl, C_{1-4} alkoxy, $C(O)NH_2$, $C(O)NH(C_{1-4}$ alkyl), $C(O)N(C_{1-4}$ alkyl)₂, CO_2H , $CO_2(C_{1-4}$ alkyl), $NHC(O)(C_{1-4}$ alkyl), $NHS(O)_2(C_{1-4}$ alkyl), $25 C(O)(C_{1-4}$ alkyl), CF_3 or OCF_3);
 alternatively NR^6R^7 , NR^8R^9 , $NR^{13}R^{14}$, $NR^{15}R^{16}$, $NR^{19}R^{20}$ or $N(C_{1-4}$ alkyl)₂ may, independently, form a 4-7 membered heterocyclic ring, azetidine, pyrrolidine, piperidine, azepine, 1,4-morpholine or 1,4-piperazine, the latter optionally substituted by C_{1-4} alkyl on the distal nitrogen;
- 30 R^{25} , R^{18} and R^{24} are, independently, C_{1-6} alkyl (optionally substituted by halogen, hydroxy or C_{3-10} cycloalkyl), $CH_2(C_{2-6}$ alkenyl), phenyl (itself optionally substituted by halogen, hydroxy, nitro, NH_2 , $NH(C_{1-4}$ alkyl), $N(C_{1-4}$ alkyl)₂ (and these alkyl groups may join to form a ring as described for R^6 and R^7 above), $S(O)_2(C_{1-4}$ alkyl), $S(O)_2NH_2$, $S(O)_2NH(C_{1-4}$

alkyl), S(O)₂N(C₁₋₄ alkyl)₂ (and these alkyl groups may join to form a ring as described for R⁶ and R⁷ above), cyano, C₁₋₄ alkyl, C₁₋₄ alkoxy, C(O)NH₂, C(O)NH(C₁₋₄ alkyl), C(O)N(C₁₋₄ alkyl)₂ (and these alkyl groups may join to form a ring as described for R⁶ and R⁷ above), CO₂H, CO₂(C₁₋₄ alkyl), NHC(O)(C₁₋₄ alkyl), NHS(O)₂(C₁₋₄ alkyl), C(O)(C₁₋₄ alkyl), CF₃ or OCF₃) or heterocyclyl (itself optionally substituted by halogen, hydroxy, nitro, NH₂, NH(C₁₋₄ alkyl), N(C₁₋₄ alkyl)₂ (and these alkyl groups may join to form a ring as described for R⁶ and R⁷ above), S(O)₂(C₁₋₄ alkyl), S(O)₂NH₂, S(O)₂NH(C₁₋₄ alkyl), S(O)₂N(C₁₋₄ alkyl)₂ (and these alkyl groups may join to form a ring as described for R⁶ and R⁷ above), cyano, C₁₋₄ alkyl, C₁₋₄ alkoxy, C(O)NH₂, C(O)NH(C₁₋₄ alkyl), C(O)N(C₁₋₄ alkyl)₂ (and these alkyl groups may join to form a ring as described for R⁶ and R⁷ above), CO₂H, CO₂(C₁₋₄ alkyl), NHC(O)(C₁₋₄ alkyl), NHS(O)₂(C₁₋₄ alkyl), C(O)(C₁₋₄ alkyl), CF₃ or OCF₃); or an N-oxide thereof; or a pharmaceutically acceptable salt thereof; or a solvate thereof.

Certain compounds of the present invention can exist in different isomeric forms (such as enantiomers, diastereomers, geometric isomers or tautomers). The present invention covers all such isomers and mixtures thereof in all proportions.

Suitable salts include acid addition salts such as a hydrochloride, dihydrochloride, hydrobromide, phosphate, sulfate, acetate, diacetate, fumarate, maleate, tartrate, citrate, oxalate, methanesulfonate or p-toluenesulfonate. Salts also include metal salts, such as alkali metal salts (for example a sodium salt).

The compounds of the invention may exist as solvates (such as hydrates) and the present invention covers all such solvates.

Halogen includes fluorine, chlorine, bromine and iodine.

Alkyl groups and moieties (including those of alkoxy) are straight or branched chain and are, for example, methyl, ethyl, n-propyl, 1-methylethyl or 1,1-dimethylethyl.

Alkenyl is, for example, vinyl or allyl.

Alkynyl is, for example, propargyl.

Cycloalkyl is mono-, bi or tricyclic and is, for example, cyclopropyl, cyclopentyl, cyclohexyl, norbornyl or camphoryl. The cycloalkyl ring is optionally fused to a benzene ring (for example forming a bicyclo[4.2.0]octa-1,3,5-trienyl or indanyl ring system).

Haloalkyl is preferably CF₃. Haloalkoxy is preferably OCF₃.

Aryl is preferably phenyl or naphthyl.

Arylalkyl is preferably aryl(C₁₋₄ alkyl) for example benzyl or 2-phenyleth-1-yl.

Heterocyclyl is an aromatic or non-aromatic 5 or 6 membered ring, optionally fused to one or more other rings, comprising at least one heteroatom selected from the group comprising nitrogen, oxygen and sulfur; or an N-oxide thereof, or an S-oxide or S-dioxide thereof. Heterocyclyl is, for example, furyl, thienyl (also known as thiophenyl), pyrrolyl, 5 2,5-dihydropyrrolyl, thiazolyl, pyrazolyl, oxazolyl, isoxazolyl, imidazolyl, piperidinyl, morpholinyl, pyridinyl (for example in 6-oxo-1,6-dihydro-pyridinyl), pyrimidinyl, indolyl, 2,3-dihydroindolyl, benzo[b]furyl (also known as benzfuryl), benz[b]thienyl (also known as benzthienyl or benzthiophenyl), 2,3-dihydrobenz[b]thienyl (for example in 1,1-dioxo-2,3-dihydrobenz[b]thienyl), indazolyl, benzimidazolyl, benztriazolyl, benzoxazolyl, 10 benzthiazolyl (for example in 1H-benzthiazol-2-one-yl), 2,3-dihydrobenzthiazolyl (for example in 2,3-dihydrobenzthiazol-2-one-yl), 1,2,3-benzothiadiazolyl, an imidazopyridinyl (such as imidazo[1,2a]pyridinyl), thieno[3,2-b]pyridin-6-yl 1,2,3-benzoxadiazolyl (also known as benzo[1,2,3]thiadiazolyl), 2,1,3-benzothiadiazolyl, benzofurazan (also known as 2,1,3-benzoxadiazolyl), quinoxaliny, dihydro-1-benzopyryliumyl (for example in a coumarinyl or a chromonyl), 3,4-dihydro-1H-2,1-benzothiazinyl (for example in 2-dioxo-3,4-dihydro-1H-2,1-benzothiazinyl), a pyrazolopyridine (for example 1H-pyrazolo[3,4-b]pyridinyl), a purine (for example in 3,7-dihydro-purin-2,6-dione-8-yl), quinolinyl, isoquinolinyl (for example in 2H-isoquinolin-1-one-yl), a naphthyridinyl (for example [1,6]naphthyridinyl or [1,8]naphthyridinyl or in 1H-[1,8]naphthyridin-4-one-yl), a 15 benzothiazinyl (for example in 4H-benzo[1,4]thiazin-3-one-yl), benzo[d]imidazo[2,1-b]thiazol-2-yl or dibenzothiophenyl (also known as dibenzothienyl); or an N-oxide thereof (such as a pyridine N-oxide), or an S-oxide or S-dioxide thereof.

An N-oxide of a compound of formula (I) is, for example, a 1-oxido-[1,4']bipiperidinyl-1'-yl compound.

In one particular aspect the present invention provides a compound of formula (I) 25 wherein: T is C(O) or S(O)₂; W is C(O) or S(O)₂; X is CH₂, O or NH; Y is CR⁵ or N; R¹ is optionally substituted aryl or optionally substituted heterocyclyl; R² is hydrogen or C₁₋₆ alkyl; R³ is hydrogen or optionally substituted C₁₋₆ alkyl; R⁴ is alkyl, optionally substituted aryl, optionally substituted aralkyl or optionally substituted heterocyclyl; R⁵ is hydrogen or C₁₋₆ alkyl; wherein the foregoing aryl and heterocyclyl moieties are optionally substituted by: halogen, cyano, nitro, hydroxy, oxo, S(O)_pR²⁵, OC(O)NR⁶R⁷, NR⁸R⁹, NR¹⁰C(O)R¹¹, NR¹²C(O)NR¹³R¹⁴, S(O)₂NR¹⁵R¹⁶, NR¹⁷S(O)₂R¹⁸, C(O)NR¹⁹R²⁰, C(O)R²¹, CO₂R²², NR²³CO₂R²⁴, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy(C₁₋₆)alkyl, C₁₋₆ alkoxy, C₁₋₆ 30

R⁶ and R⁷ above), cyano, C₁₋₄ alkyl, C₁₋₄ alkoxy, C(O)NH₂, C(O)NH(C₁₋₄ alkyl), C(O)N(C₁₋₄ alkyl)₂ (and these alkyl groups may join to form a ring as described for R⁶ and R⁷ above), CO₂H, CO₂(C₁₋₄ alkyl), NHC(O)(C₁₋₄ alkyl), NHS(O)₂(C₁₋₄ alkyl), C(O)(C₁₋₄ alkyl), CF₃ or OCF₃); or an N-oxide thereof; or a pharmaceutically acceptable salt thereof;

5 or a solvate thereof.

In a further aspect X is O.

In another aspect R¹ is phenyl substituted with one or more of fluorine, chlorine, C₁₋₄ alkyl (especially methyl) or C₁₋₄ alkoxy (especially methoxy).

In a further aspect R¹ is phenyl optionally substituted (for example with one, two or 10 three of) by halogen (especially fluoro or chloro), C₁₋₄ alkyl (especially methyl) or C₁₋₄ alkoxy (especially methoxy). In a still further aspect R¹ is phenyl substituted by one, two or three of: fluoro, chloro, methyl or methoxy. In another aspect R¹ is phenyl optionally substituted by halogen (especially fluoro or chloro), C₁₋₄ alkyl (especially methyl); especially optionally substituted (for example independently with one, two or three of, 15 especially two or three of) by fluoro, chloro or methyl. In a still further aspect R¹ is 3,4-dichlorophenyl, or, additionally 2-chloro-4-fluorophenyl, 2-methyl-4-chlorophenyl, 2,4-dichloro-3-methylphenyl or 3,4-dichloro-2-methylphenyl.

In another aspect one of T and W is C(O) and the other is S(O)₂.

In a still further aspect T is C(O).

20 In another aspect W is S(O)₂.

In yet another aspect of the invention, and when Y is CR⁵, the compounds of formula (I) are preferably trans in terms of relative stereochemistry, that is, the piperidine ring and the T-N(R³)-W-R⁴ group are both equatorial on the cyclohexane ring.

In a still further aspect of the invention Y is CH or N; especially N.

25 In yet another aspect R² is hydrogen or methyl; for example R² is hydrogen.

In a further aspect R³ is hydrogen or methyl; for example hydrogen.

In a still further aspect R⁴ is unsubstituted phenyl, mono-substituted phenyl, unsubstituted heterocyclyl or mono-substituted heterocyclyl, the substituents being chosen from those described above.

30 In a further aspect the present invention provides a compound of formula (I) wherein R⁴ is aryl (for example phenyl or naphthyl; especially phenyl) optionally substituted by one or more of C₁₋₆ alkyl (for example methyl or ethyl), C₁₋₄ alkoxy (for example methoxy), halogen (for example chloro or fluoro), CF₃, CN, CO₂(C₁₋₄ alkyl) (for example CO₂CH₃),

- OH, OCF₃, S(O)₂(C₁₋₄ alkyl) (for example S(O)₂CH₃) or NR⁸R⁹ (wherein R⁸ and R⁹ are, independently, hydrogen or C₁₋₄ alkyl); or heterocyclyl (for example imidazolyl, thiienyl, tetrahydrothienyl, thiazolyl, 1,3,4-thiadiazolyl, pyridyl or dihydroisoquinolinyl) optionally substituted by oxo, halogen (for example chloro or fluoro), C₁₋₄ alkyl (for example methyl),
- 5 NR⁸R⁹ (wherein R⁸ and R⁹ are, independently, hydrogen or C₁₋₄ alkyl), piperidinyl or morpholinyl. In another aspect R⁴ is phenyl optionally substituted by one or more of C₁₋₆ alkyl (for example methyl or ethyl), C₁₋₄ alkoxy (for example methoxy), halogen (for example chloro or fluoro), CF₃, CN, CO₂(C₁₋₄ alkyl) (for example CO₂CH₃), OH, OCF₃, S(O)₂(C₁₋₄ alkyl) (for example S(O)₂CH₃) or NR⁸R⁹ (wherein R⁸ and R⁹ are,
- 10 independently, hydrogen or C₁₋₄ alkyl).

In a further aspect of the invention R⁴ is substituted (especially mono-substituted) phenyl, the substituents being chosen from those described above.

- In a still further aspect R⁴ is phenyl or heterocyclyl, either of which is optionally substituted by: halo, hydroxy, nitro, cyano, oxo, amino, C₁₋₄ alkyl (itself optionally substituted by S(O)₂(C₁₋₄ alkyl), S(O)₂phenyl), C₁₋₄ alkoxy, S(O)_kR²⁶ (wherein k is 0, 1 or 2 (preferably 2); and R²⁶ is C₁₋₄ alkyl, C₁₋₄ hydroxyalkyl, C₃₋₇ cycloalkyl(C₁₋₄ alkyl) (such as cyclopropylmethyl) or phenyl), C₁₋₄ haloalkylthio, C(O)NH₂, NHS(O)₂(C₁₋₄ alkyl), S(O)₂NH₂, S(O)₂NH(C₁₋₄ alkyl) or S(O)₂N(C₁₋₄ alkyl)₂.

- In yet another aspect R⁴ is phenyl or heterocyclyl, either of which is optionally substituted by: halo, hydroxy, nitro, cyano, oxo, NR⁸R⁹ (wherein R⁸ and R⁹ are, independently, hydrogen or C₁₋₆ alkyl), C₁₋₄ alkyl (itself optionally substituted by S(O)₂(C₁₋₄ alkyl), S(O)₂phenyl), C₁₋₄ alkoxy, S(O)_kR²⁶ (wherein k is 0, 1 or 2 (preferably 2); and R²⁶ is C₁₋₄ alkyl, C₁₋₄ hydroxyalkyl, C₃₋₇ cycloalkyl(C₁₋₄ alkyl) (such as cyclopropylmethyl) or phenyl), C₁₋₄ haloalkylthio, C(O)NH₂, NHS(O)₂(C₁₋₄ alkyl), S(O)₂NH₂, S(O)₂NH(C₁₋₄ alkyl) or S(O)₂N(C₁₋₄ alkyl)₂.

- In one aspect the variable R⁴ is phenyl optionally substituted by: halo, hydroxy, nitro, cyano, amino, C₁₋₄ alkyl (itself optionally substituted by S(O)₂(C₁₋₄ alkyl), S(O)₂phenyl), C₁₋₄ alkoxy, S(O)_kR²⁶ (wherein k is 0, 1 or 2 (preferably 2); and R²⁶ is C₁₋₄ alkyl, C₁₋₄ hydroxyalkyl, C₃₋₇ cycloalkyl(C₁₋₄ alkyl) (such as cyclopropylmethyl) or phenyl), C₁₋₄ haloalkylthio, C(O)NH₂, NHS(O)₂(C₁₋₄ alkyl), S(O)₂NH₂, S(O)₂NH(C₁₋₄ alkyl) or S(O)₂N(C₁₋₄ alkyl)₂ (and these alkyl groups may join to form a ring as described for R⁶ and R⁷ above).

In another aspect the variable R⁴ is phenyl optionally substituted by: halo, hydroxy, nitro, cyano, NR⁸R⁹ (wherein R⁸ and R⁹ are, independently, hydrogen or C₁₋₆ alkyl), C₁₋₄ alkyl (itself optionally substituted by S(O)₂(C₁₋₄ alkyl), S(O)₂phenyl), C₁₋₄ alkoxy, S(O)_kR²⁶ (wherein k is 0, 1 or 2 (preferably 2); and R²⁶ is C₁₋₄ alkyl, C₁₋₄ hydroxyalkyl, C₃₋₇ cycloalkyl(C₁₋₄ alkyl) (such as cyclopropylmethyl) or phenyl), C₁₋₄ haloalkylthio, C(O)NH₂, NHS(O)₂(C₁₋₄ alkyl), S(O)₂NH₂, S(O)₂NH(C₁₋₄ alkyl) or S(O)₂N(C₁₋₄ alkyl)₂ (and these alkyl groups may join to form a ring as described for R⁶ and R⁷ above).

In another aspect the variable R⁴ is phenyl optionally substituted by: halo, hydroxy, nitro, cyano, amino, C₁₋₄ alkyl (itself optionally substituted by S(O)₂phenyl), C₁₋₄ alkoxy, S(O)_kR²⁶ (wherein k is 0, 1 or 2; and R²⁶ is C₁₋₄ alkyl or phenyl) or C₁₋₄ haloalkylthio.

In a further aspect the variable R⁴ is phenyl optionally substituted by: halo, hydroxy, nitro, cyano, NR⁸R⁹ (wherein R⁸ and R⁹ are, independently, hydrogen or C₁₋₄ alkyl), C₁₋₄ alkyl (itself optionally substituted by S(O)₂phenyl), C₁₋₄ alkoxy, S(O)_kR²⁶ (wherein k is 0, 1 or 2; and R²⁶ is C₁₋₄ alkyl or phenyl) or C₁₋₄ haloalkylthio.

The amine group NR⁸R⁹ is, for example, mono-(C₁₋₄) alkylamino (such as NHCH₃ or NHCH₂CH₃) or di-(C₁₋₄) alkylamino (such as N(CH₃)₂).

In yet another aspect of the invention R⁴ is phenyl mono-substituted with halogen (for example fluorine or chlorine), C₁₋₄ alkyl (for example methyl or ethyl), C₁₋₄ alkoxy (for example methoxy or ethoxy) or NR⁸R⁹ (wherein R⁸ and R⁹ are, independently, hydrogen or C₁₋₆ alkyl; and NR⁸R⁹ is especially NHCH₃, NHCH₂CH₃ or N(CH₃)₂).

In a further aspect R⁴ is phenyl substituted with halogen, alkyl or alkoxy.


In a still further aspect of the invention R⁴ is phenyl mono-substituted with halogen (especially chlorine) or C₁₋₄ alkyl (especially methyl).

In yet another aspect R⁵ is hydrogen.

In another aspect the present invention provides a pharmaceutically acceptable salt of a compound of formula (I), for example a metal salt {such as an alkali metal salt (for example the sodium salt)} of a compound of formula (I).


Compounds of formula (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig) and (Ih) are examples of compounds of formula (I).

In a still further aspect the present invention provides a compound of formula (Ia):




wherein: X, R¹, R², R³ and R⁴ are as defined above; or a pharmaceutically acceptable salt thereof.

In a still further aspect the present invention provides a compound of formula (Ib):




5 wherein: X, R¹, R², R³ and R⁴ are as defined above; or a pharmaceutically acceptable salt thereof.

In a still further aspect the present invention provides a compound of formula (Ic):




10 wherein: X, R¹, R², R³, R⁴ and R⁵ are as defined above; or a pharmaceutically acceptable salt thereof. In another aspect the compounds of formula (Ic) are preferably trans in terms of relative stereochemistry, that is, the piperidine ring and the C(O)N(R³)S(O)₂R⁴ group are both equatorial on the cyclohexane ring.

In a still further aspect the present invention provides a compound of formula (Id):




15 wherein: X, R¹, R², R³ and R⁴ are as defined above; or a pharmaceutically acceptable salt thereof.

In a still further aspect the present invention provides a compound of formula (Ie):




20 wherein: X, R¹, R², R³ and R⁴ are as defined above; or a pharmaceutically acceptable salt thereof.

In a still further aspect the present invention provides a compound of formula (If):




wherein: X, R¹, R², R³, R⁴ and R⁵ are as defined above; or a pharmaceutically acceptable salt thereof. In another aspect the compounds of formula (If) are preferably trans in terms of relative stereochemistry, that is, the piperidine ring and the S(O)₂N(R³)C(O)R⁴ group are both equatorial on the cyclohexane ring.

In a still further aspect the present invention provides a compound of formula (Ig):



wherein: X, R¹, R², R³, R⁴ and R⁵ are as defined above; or a pharmaceutically acceptable salt thereof. In another aspect the compounds of formula (Ig) are preferably trans in terms of relative stereochemistry, that is, the piperidine ring and the C(O)N(R³)C(O)R⁴ group are both equatorial on the cyclohexane ring.

In a still further aspect the present invention provides a compound of formula (Ih):



wherein: X, R¹, R², R³, R⁴ and R⁵ are as defined above; or a pharmaceutically acceptable salt thereof. In another aspect the compounds of formula (Ih) are preferably trans in terms of relative stereochemistry, that is the piperidine ring and the S(O)₂N(R³)S(O)₂R⁴ group are both equatorial on the cyclohexane ring.

A compound of formula (Ia) is, for example:

20 N-[[4-(2-Chloro-4-fluorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methylbenzenesulfonamide;

N-[[4-(2-Chloro-4-fluorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-2-methylbenzenesulfonamide;

4-Chloro-N-[[4-(2-chloro-4-fluorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-benzenesulfonamide;

2-Chloro-*N*-[[4-(2-chloro-4-fluorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-benzenesulfonamide;

N-[[4-(2-Chloro-4-fluorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-fluoro-benzenesulfonamide;

- 5 *N*-[[4-(2-Chloro-4-fluorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-benzenesulfonamide;
N-[[4-(4-Chloro-2-methylphenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-2-methyl-benzenesulfonamide;

4-Chloro-*N*-[[4-(4-chloro-2-methylphenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-benzenesulfonamide;

- 10 2-Chloro-*N*-[[4-(4-chloro-2-methylphenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-benzenesulfonamide;

N-[[4-(4-Chloro-2-methylphenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-fluoro-benzenesulfonamide;

- 15 *N*-[[4-(4-Chloro-2-methylphenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide;

N-[[4-(4-Chloro-2-methylphenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-benzenesulfonamide;

N-[[4-(2,4-Dichloro-3-methylphenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-2-methyl-benzenesulfonamide;

N-[[4-(2,4-Dichloro-3-methylphenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-

- 20 benzenesulfonamide;

2-Chloro-*N*-[[4-(2,4-dichloro-3-methylphenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-benzenesulfonamide;

4-Chloro-*N*-[[4-(2,4-dichloro-3-methylphenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-benzenesulfonamide;

- 25 *N*-[[4-(2,4-Dichloro-3-methylphenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-fluoro-benzenesulfonamide;

N-[[4-(2,4-Dichloro-3-methylphenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-benzenesulfonamide;

N-[[4-(3,4-Dichloro-2-methylphenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-2-methyl-

- 30 benzenesulfonamide;

N-[[4-(3,4-Dichloro-2-methylphenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide;

- 2-Chloro-*N*-[[4-(3,4-dichloro-2-methylphenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-benzenesulfonamide;
- 4-Chloro-*N*-[[4-(3,4-dichloro-2-methylphenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-benzenesulfonamide;
- 5 *N*-[[4-(3,4-Dichloro-2-methylphenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-fluoro-benzenesulfonamide;
- N*-[[4-(3,4-Dichloro-2-methylphenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-benzenesulfonamide;
- N*-[[4-(3,4-Dichlorophenoxy)-4'-methyl[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-10 benzenesulfonamide;
- N*-[[4-(3,4-Dichlorophenoxy)-4'-methyl[1,4'-bipiperidin]-1'-yl]carbonyl]-4-fluoro-benzenesulfonamide;
- N*-[[4-(3,4-Dichlorophenoxy)-4'-methyl[1,4'-bipiperidin]-1'-yl]carbonyl]-2-methyl-benzenesulfonamide;
- 15 4-Chloro-*N*-[[4-(3,4-dichlorophenoxy)-4'-methyl[1,4'-bipiperidin]-1'-yl]carbonyl]-benzenesulfonamide;
- 2-Chloro-*N*-[[4-(3,4-dichlorophenoxy)-4'-methyl[1,4'-bipiperidin]-1'-yl]carbonyl]-benzenesulfonamide;
- N*-[[4-(3,4-Dichlorophenoxy)-4'-methyl[1,4'-bipiperidin]-1'-yl]carbonyl]-3-trifluoromethyl-20 benzenesulfonamide;
- 3-Cyano-*N*-[[4-(3,4-dichlorophenoxy)-4'-methyl[1,4'-bipiperidin]-1'-yl]carbonyl]-benzenesulfonamide;
- N*-[[4-(3,4-Dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-benzenemethanesulfonamide;
- 25 *N*-[[4-(3,4-Dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]- methanesulfonamide;
- N*-[[4-(4-Chloro-3-methylphenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-2-methyl-benzenesulfonamide;
- N*-[[4-(4-Chloro-3-methylphenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide;
- 30 4-Chloro-*N*-[[4-(4-chloro-3-methylphenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-benzenesulfonamide;
- N*-[[4-(3,4-Dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-*N*,4-dimethyl-benzenesulfonamide;

N-[[4-[(3,4-Dichlorophenyl)methyl][1,4'-bipiperidin]-1'-yl]carbonyl]-4-methylbenzenesulfonamide;

4-Chloro-*N*-[[4-[(3,4-dichlorophenyl)methyl][1,4'-bipiperidin]-1'-yl]carbonyl]-benzenesulfonamide;

5 *N*-[[4-[(3,4-Dichlorophenyl)amino][1,4'-bipiperidin]-1'-yl]carbonyl]-4-methylbenzenesulfonamide;

4-Chloro-*N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-benzenesulfonamide;

10 *N*-[[4-(3,4-Dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methylbenzenesulfonamide;

N-[[4-(3,4-Dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-2-methylbenzenesulfonamide;

3-Bromo-*N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-benzenesulfonamide;

15 4-Bromo-*N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-benzenesulfonamide;

3,5-Dichloro-*N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-benzenesulfonamide;

20 3-Cyano-*N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-benzenesulfonamide;

N-[[4-(3,4-Dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-2,5-dimethoxybenzenesulfonamide;

25 *N*-[[4-(3,4-Dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-3,4-dimethoxybenzenesulfonamide;

N-[[4-(3,4-Dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-(3,3-dimethyl-2-oxo-1-azetidinyl)-benzenesulfonamide;

N-[[4-(3,4-Dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-(4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)-benzenesulfonamide;

30 N-[[4-(3,4-Dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-3-(4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)-benzenesulfonamide;

N-[[4-(3,4-Dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-hydroxybenzenesulfonamide;

- N-[[4-(3,4-Dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-3-(trifluoromethyl)-benzenesulfonamide;
- N-[[4-(3,4-Dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-benzenesulfonamide;
- 4-[[[[4-(3,4-Dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]amino]sulfonyl]-benzoic acid, methyl ester;
- 2-Bromo-N-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-benzenesulfonamide;
- N-[5-[[[4-(3,4-Dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]amino]sulfonyl]-1,3,4-thiadiazol-2-yl]-acetamide;
- 10 N-[[4-(3,4-Dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-5-(dimethylamino)-1-naphthalenesulfonamide;
- N-[[4-(3,4-Dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-2-naphthalenesulfonamide;
- N-[[4-(3,4-Dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-2,4-dimethyl-5-thiazolesulfonamide;
- 15 N-[[4-(3,4-Dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-2-(1-piperidinyl)-3-pyridinesulfonamide;
- 5-Chloro-N-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-2-thiophenesulfonamide;
- 5-Bromo-N-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-2-thiophenesulfonamide;
- 20 N-[[4-(3,4-Dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]tetrahydro-3-thiophenesulfonamide; 1,1-dioxide
- 4,5-Dichloro-N-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-2-thiophenesulfonamide;
- 25 4-Chloro-N-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-2,5-dimethyl-benzenesulfonamide;
- 4-n-Butyl-N-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-benzenesulfonamide;
- 2,5-Dichloro-N-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-3-
- 30 thiophenesulfonamide;
- 4-n-Butoxy-N-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-benzenesulfonamide;

- N-[[4-(3,4-Dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-2-(trifluoromethoxy)-benzenesulfonamide;
- N-[[4-(3,4-Dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-1-methyl-1H-imidazole-4-sulfonamide;
- 5 5-Amino-N-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-1,3,4-thiadiazole-2-sulfonamide;
- 4-Bromo-N-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-2-thiophenesulfonamide;
- N-[[4-(3,4-Dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-2-(4-morpholinyl)-3-pyridinesulfonamide;
- 10 6-Bromo-N-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-3-pyridinesulfonamide;
- N-[[4-(3,4-Dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-(1,1-dimethylethyl)-benzenesulfonamide;
- 15 N-[[4-(3,4-Dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-5-methyl-2-pyridinesulfonamide;
- N-[[4-(3,4-Dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-2,5-difluoro-benzenesulfonamide;
- N-[[4-(3,4-Dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-(trifluoromethoxy)-benzenesulfonamide;
- 20 5-Chloro-N-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-2,4,5-trifluoro-benzenesulfonamide;
- N-[[4-(3,4-Dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-2,4,5-difluoro-benzenesulfonamide;
- 25 4-Chloro-N-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-2,5-difluoro-benzenesulfonamide;
- 3-Chloro-N-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-5-fluoro-2-methyl-benzenesulfonamide;
- N-[[4-(2,4-dichloro-3-methylphenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-fluoro-benzenesulfonamide;
- 30 2-chloro-N-[[4-(2,4-dichloro-3-methylphenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-benzenesulfonamide;

N-[[4-(3,4-dichloro-2-methylphenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methylbenzenesulfonamide;

2-chloro-N-[[4-(3,4-dichloro-2-methylphenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-benzenesulfonamide;

5 N-[[4-(4-chlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide;

N-[[4-(2,4-dichloro-3-methylphenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-2-methylbenzenesulfonamide;

N-[[4-(2,4-dichloro-3-fluorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methylbenzenesulfonamide;

10 N-[[4-(4-chloro-2-methylphenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-2-methylbenzenesulfonamide;

2-chloro-N-[[4-(4-chloro-2-methylphenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-benzenesulfonamide;

4-chloro-N-[[4-(4-chloro-2-methylphenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-

15 benzenesulfonamide;

N-[[4-(2,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methylbenzenesulfonamide;

N-[[4-(3-chlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide;

2-chloro-N-[[4-(3-chlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-benzenesulfonamide;

20 N-[[4-(3-chlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-benzenesulfonamide;

2-chloro-N-[[4-(3-chloro-2-methylphenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-benzenesulfonamide;

N-[[4-(2-chloro-4-fluorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-2-methylbenzenesulfonamide;

25 2-chloro-N-[[4-(2,4-dichloro-3-fluorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-benzenesulfonamide;

4-chloro-N-[[4-(2,4-dichloro-3-fluorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-benzenesulfonamide;

N-[[4-(2,4-dichloro-3-fluorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-2-methyl-

30 benzenesulfonamide;

2-chloro-N-[[4-(4-chlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-benzenesulfonamide;

4-chloro-N-[[4-(4-chlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-benzenesulfonamide;

N-[[4-(4-chlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-2-methyl-benzenesulfonamide;

2-chloro-N-[[4-(2,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-benzenesulfonamide;

4-chloro-N-[[4-(2,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-benzenesulfonamide;

5 N-[[4-(2,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-2-methyl-benzenesulfonamide;

2-chloro-N-[[4-(3,4-difluorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-benzenesulfonamide;

10 N-[[4-(3,4-difluorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-2-methyl-benzenesulfonamide;

N-[[4-(3,4-difluorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide;

N-[[4-(3-chloro-2-methylphenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide;

15 N-[[4-(3-chloro-2-methylphenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-benzenesulfonamide;

3-chloro-N-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-benzenesulfonamide;

N-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methoxy-benzenesulfonamide;

20 N-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-2,4,5-trifluoro-benzenesulfonamide;

N-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-2,5-difluoro-benzenesulfonamide;

25 N-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-(dimethylamino)-benzenesulfonamide;

N-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-2-methoxy-benzenesulfonamide;

4-bromo-N-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-benzenesulfonamide;

30 3,5-dichloro-N-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-benzenesulfonamide;

Methyl 2-[[[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]amino]sulfonyl]-benzoate;

- 2-bromo-N-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-benzenesulfonamide;
- 5-chloro-N-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-2-thiophenesulfonamide;
- 5 4,5-dichloro-N-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-2-thiophenesulfonamide;
- 4-chloro-N-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-2,5-dimethyl-benzenesulfonamide;
- 2,5-dichloro-N-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-3-thiophenesulfonamide;
- 10 N-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-2-(trifluoromethoxy)-benzenesulfonamide;
- 4-bromo-N-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-2-thiophenesulfonamide;
- 15 N-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-(trifluoromethoxy)-benzenesulfonamide;
- 5-chloro-N-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-2,4-difluoro-benzenesulfonamide;
- 4-chloro-N-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-2,5-difluoro-benzenesulfonamide;
- 20 3-chloro-N-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-5-fluoro-2-methyl-benzenesulfonamide;
- N-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-2,6-dimethyl-benzenesulfonamide; or,
- 25 N-[[4-(3,4-Dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-2-propanesulfonamide.

A compound of formula (Ib) is, for example:

- 4-(3,4-Dichlorophenoxy)-N-(4-methylbenzoyl)-[1,4'-bipiperidine]-1'-sulfonamide;
- 4-(3,4-dichlorophenoxy)-N-(4-fluorobenzoyl)-[1,4'-bipiperidine]-1'-sulfonamide;
- 30 N-(4-chlorobenzoyl)-4-(3,4-dichlorophenoxy)-[1,4'-bipiperidine]-1'-sulfonamide;
- 4-(3,4-dichlorophenoxy)-N-(4-methylbenzoyl)-[1,4'-bipiperidine]-1'-sulfonamide;
- 4-(3,4-dichlorophenoxy)-N-[4-(dimethylamino)benzoyl]-[1,4'-bipiperidine]-1'-sulfonamide;

- 4-(3,4-dichlorophenoxy)-N-(4-ethylbenzoyl)-[1,4'-bipiperidine]-1'-sulfonamide;
4-(3,4-dichlorophenoxy)-N-(2-methoxybenzoyl)-[1,4'-bipiperidine]-1'-sulfonamide;
4-(3,4-dichlorophenoxy)-N-(4-methoxybenzoyl)-[1,4'-bipiperidine]-1'-sulfonamide;
N-(2-chlorobenzoyl)-4-(3,4-dichlorophenoxy)-[1,4'-bipiperidine]-1'-sulfonamide;
5. 4-(3,4-dichlorophenoxy)-N-[3-(methylsulfonyl)benzoyl]-[1,4'-bipiperidine]-1'-sulfonamide;
N-(3-cyanobenzoyl)-4-(3,4-dichlorophenoxy)-[1,4'-bipiperidine]-1'-sulfonamide;
4-(4-chloro-2-methylphenoxy)-N-(4-fluorobenzoyl)-[1,4'-bipiperidine]-1'-sulfonamide;
N-(4-chlorobenzoyl)-4-(4-chloro-2-methylphenoxy)-[1,4'-bipiperidine]-1'-sulfonamide;
- 10 4-(4-chloro-2-methylphenoxy)-N-(4-methylbenzoyl)-[1,4'-bipiperidine]-1'-sulfonamide;
4-(4-chloro-2-methylphenoxy)-N-[4-(dimethylamino)benzoyl]-[1,4'-bipiperidine]-1'-sulfonamide;
4-(4-chloro-2-methylphenoxy)-N-(4-ethylbenzoyl)-[1,4'-bipiperidine]-1'-sulfonamide;
4-(4-chloro-2-methylphenoxy)-N-(2-methoxybenzoyl)-[1,4'-bipiperidine]-1'-sulfonamide;
- 15 4-(4-chloro-2-methylphenoxy)-N-(4-methoxybenzoyl)-[1,4'-bipiperidine]-1'-sulfonamide;
N-(2-chlorobenzoyl)-4-(4-chloro-2-methylphenoxy)-[1,4'-bipiperidine]-1'-sulfonamide;
4-(4-chloro-2-methylphenoxy)-N-[3-(methylsulfonyl)benzoyl]-[1,4'-bipiperidine]-1'-sulfonamide;
4-(4-chloro-2-methylphenoxy)-N-(3-cyanobenzoyl)-[1,4'-bipiperidine]-1'-sulfonamide;
- 20 4-(2,4-dichloro-3-methylphenoxy)-N-(4-fluorobenzoyl)-[1,4'-bipiperidine]-1'-sulfonamide;
N-(4-chlorobenzoyl)-4-(2,4-dichloro-3-methylphenoxy)-[1,4'-bipiperidine]-1'-sulfonamide;
4-(2,4-dichloro-3-methylphenoxy)-N-(4-methylbenzoyl)-[1,4'-bipiperidine]-1'-sulfonamide;
4-(2,4-dichloro-3-methylphenoxy)-N-[4-(dimethylamino)benzoyl]-[1,4'-bipiperidine]-1'-sulfonamide;
- 25 4-(2,4-dichloro-3-methylphenoxy)-N-(4-ethylbenzoyl)-[1,4'-bipiperidine]-1'-sulfonamide;
4-(2,4-dichloro-3-methylphenoxy)-N-(2-methoxybenzoyl)-[1,4'-bipiperidine]-1'-sulfonamide;
4-(2,4-dichloro-3-methylphenoxy)-N-(4-methoxybenzoyl)-[1,4'-bipiperidine]-1'-sulfonamide;
- 30 N-(2-chlorobenzoyl)-4-(2,4-dichloro-3-methylphenoxy)-[1,4'-bipiperidine]-1'-sulfonamide;
4-(2,4-dichloro-3-methylphenoxy)-N-[3-(methylsulfonyl)benzoyl]-[1,4'-bipiperidine]-1'-sulfonamide;

- N-(3-cyanobenzoyl)-4-(3,4-dichlorophenoxy)-[1,4'-bipiperidine]-1'-sulfonamide;
4-(3,4-dichloro-2-methylphenoxy)-N-(4-fluorobenzoyl)-[1,4'-bipiperidine]-1'-sulfonamide;
N-(4-chlorobenzoyl)-4-(3,4-dichloro-2-methylphenoxy)-[1,4'-bipiperidine]-1'-sulfonamide;
4-(3,4-dichloro-2-methylphenoxy)-N-(4-methylbenzoyl)-[1,4'-bipiperidine]-1'-
5 sulfonamide;
4-(3,4-dichloro-2-methylphenoxy)-N-[4-(dimethylamino)benzoyl]-[1,4'-bipiperidine]-1'-
sulfonamide;
4-(3,4-dichloro-2-methylphenoxy)-N-(4-ethylbenzoyl)-[1,4'-bipiperidine]-1'-sulfonamide;
4-(3,4-dichloro-2-methylphenoxy)-N-(2-methoxybenzoyl)-[1,4'-bipiperidine]-1'-
10 sulfonamide;
4-(3,4-dichloro-2-methylphenoxy)-N-(4-methoxybenzoyl)-[1,4'-bipiperidine]-1'-
sulfonamide;
N-(2-chlorobenzoyl)-4-(3,4-dichloro-2-methylphenoxy)-[1,4'-bipiperidine]-1'-sulfonamide;
4-(3,4-dichloro-2-methylphenoxy)-N-[3-(methylsulfonyl)benzoyl]-[1,4'-bipiperidine]-1'-
15 sulfonamide;
N-(3-cyanobenzoyl)-4-(3,4-dichloro-2-methylphenoxy)-[1,4'-bipiperidine]-1'-sulfonamide;
N-benzoyl-4-(3,4-dichloro-2-methylphenoxy)-[1,4'-bipiperidine]-1'-sulfonamide;
N-benzoyl-4-(2,4-dichlorophenoxy)-[1,4'-bipiperidine]-1'-sulfonamide;
N-(3-cyanobenzoyl)-4-(3,4-dichlorophenoxy)-[1,4'-bipiperidine]-1'-sulfonamide;
20 4-(3,4-dichlorophenoxy)-N-(4-fluorobenzoyl)-[1,4'-bipiperidine]-1'-sulfonamide;
4-(3,4-dichlorophenoxy)-N-[3-(methylsulfonyl)benzoyl]-[1,4'-bipiperidine]-1'-
sulfonamide;
4-(4-chloro-2-methylphenoxy)-N-[3-(methylsulfonyl)benzoyl]-[1,4'-bipiperidine]-1'-
sulfonamide;
25 N-(2-chlorobenzoyl)-4-(3,4-dichlorophenoxy)-[1,4'-bipiperidine]-1'-sulfonamide;
N-(4-chlorobenzoyl)-4-(3,4-dichlorophenoxy)-[1,4'-bipiperidine]-1'-sulfonamide;
N-(4-chlorobenzoyl)-4-(4-chloro-2-methylphenoxy)-[1,4'-bipiperidine]-1'-sulfonamide;
4-(3,4-dichlorophenoxy)-N-(2-methoxybenzoyl)-[1,4'-bipiperidine]-1'-sulfonamide;
4-(3,4-dichlorophenoxy)-N-(4-methoxybenzoyl)-[1,4'-bipiperidine]-1'-sulfonamide;
30 4-(3,4-dichlorophenoxy)-N-(4-methylbenzoyl)-[1,4'-bipiperidine]-1'-sulfonamide;
4-(3,4-dichlorophenoxy)-N-[(1,2-dihydro-1-oxo-4-isoquinolinyl)carbonyl]-[1,4'-
bipiperidine]-1'-sulfonamide;
N-(cyclohexylcarbonyl)-4-(3,4-dichlorophenoxy)-[1,4'-bipiperidine]-1'-sulfonamide;

4-(3,4-dichlorophenoxy)-*N*-(2-methyl-1-oxopropyl)-[1,4'-bipiperidine]-1'-sulfonamide;
4-(3,4-dichlorophenoxy)-*N*-(2-phenylacetyl)-[1,4'-bipiperidine]-1'-sulfonamide; or,
N-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-2-propanesulfonamide.

5 A compound of formula (Ic) is, for example:

Trans *N*-[[4-[4-(3,4-Dichlorophenoxy)-1-piperidinyl]cyclohexyl]carbonyl]-4-methylbenzenesulfonamide;

Trans *N*-[[4-[4-(3,4-Dichlorophenoxy)-1-piperidinyl]cyclohexyl]carbonyl]-*N*,4-dimethylbenzenesulfonamide;

10 Trans 4-chloro-*N*-[[4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]cyclohexyl]carbonyl]-benzenesulfonamide;

Trans *N*-[[4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]cyclohexyl]carbonyl]-4-methylbenzenesulfonamide;

Trans *N*-[[4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]cyclohexyl]carbonyl]-2-methylbenzenesulfonamide;

15 Trans 3-bromo-*N*-[[4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]cyclohexyl]carbonyl]-benzenesulfonamide;

Trans 4-bromo-*N*-[[4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]cyclohexyl]carbonyl]-benzenesulfonamide;

20 Trans 3,5-dichloro-*N*-[[4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]cyclohexyl]carbonyl]-benzenesulfonamide;

Trans 3-cyano-*N*-[[4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]cyclohexyl]carbonyl]-benzenesulfonamide;

25 Trans *N*-[[4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]cyclohexyl]carbonyl]-2,5-dimethoxybenzenesulfonamide;

Trans *N*-[[4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]cyclohexyl]carbonyl]-3,4-dimethoxybenzenesulfonamide;

Trans *N*-[[4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]cyclohexyl]carbonyl]-4-(3,3-dimethyl-2-oxo-1-azetidinyl)-benzenesulfonamide;

30 Trans *N*-[[4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]cyclohexyl]carbonyl]-4-(4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)-benzenesulfonamide;

Trans *N*-[[4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]cyclohexyl]carbonyl]-3-(4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)-benzenesulfonamide;

- Trans N-[[4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]cyclohexyl]carbonyl]-4-hydroxybenzenesulfonamide;
- Trans N-[[4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]cyclohexyl]carbonyl]-3-(trifluoromethyl)-benzenesulfonamide;
- 5 Trans N-[[4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]cyclohexyl]carbonyl]-benzenesulfonamide;
- Trans 2-[[[[4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]cyclohexyl]carbonyl]amino]-sulfonyl]-benzoic acid, methyl ester;
- Trans 2-bromo-N-[[4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]cyclohexyl]carbonyl]-10 benzenesulfonamide;
- Trans N-[5-[[[[4-(3,4-dichlorophenoxy)-1-piperidinyl]cyclohexyl]carbonyl]amino]sulfonyl]-1,3,4-thiadiazol-2-yl]-acetamide;
- Trans N-[[4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]cyclohexyl]carbonyl]-5-(dimethylamino)-1-naphthalenesulfonamide;
- 15 Trans N-[[4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]cyclohexyl]carbonyl]-2-naphthalenesulfonamide;
- Trans N-[[4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]cyclohexyl]carbonyl]-2,4-dimethyl-5-thiazolesulfonamide;
- Trans N-[[4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]cyclohexyl]carbonyl]-2-(1-piperidinyl)-3-pyridinesulfonamide;
- 20 Trans 5-chloro-N-[[4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]cyclohexyl]carbonyl]-2-thiophenesulfonamide;
- Trans 5-bromo-N-[[4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]cyclohexyl]carbonyl]-2-thiophenesulfonamide;
- 25 Trans N-[[4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]cyclohexyl]carbonyl]tetrahydro-3-thiophenesulfonamide, 1,1-dioxide;
- Trans 4,5-dichloro-N-[[4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]cyclohexyl]carbonyl]-2-thiophenesulfonamide;
- Trans 4-chloro-N-[[4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]cyclohexyl]carbonyl]-2,5-dimethyl-benzenesulfonamide;
- 30 Trans 4-n-butyl-N-[[4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]cyclohexyl]carbonyl]-benzenesulfonamide;

- Trans 2,5-dichloro-N-[[4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]cyclohexyl]carbonyl]-3-thiophenesulfonamide;
- Trans 4-n-butoxy-N-[[4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]cyclohexyl]carbonyl]-benzenesulfonamide;
- 5 Trans N-[[4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]cyclohexyl]carbonyl]-2-(trifluoromethoxy)-benzenesulfonamide;
- Trans N-[[4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]cyclohexyl]carbonyl]-1-methyl-1H-imidazole-4-sulfonamide;
- Trans 5-amino-N-[[4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]cyclohexyl]carbonyl]-1,3,4-thiadiazole-2-sulfonamide;
- 10 Trans 4-bromo-N-[[4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]cyclohexyl]carbonyl]-2-thiophenesulfonamide;
- Trans N-[[4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]cyclohexyl]carbonyl]-2-(4-morpholinyl)-3-pyridinesulfonamide;
- 15 Trans 6-bromo-N-[[4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]cyclohexyl]carbonyl]-3-pyridinesulfonamide;
- Trans N-[[4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]cyclohexyl]carbonyl]-4-(1,1-dimethylethyl)-benzenesulfonamide;
- 20 Trans N-[[4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]cyclohexyl]carbonyl]-5-methyl-2-pyridinesulfonamide;
- Trans N-[[4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]cyclohexyl]carbonyl]-2,5-difluoro-benzenesulfonamide;
- Trans N-[[4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]cyclohexyl]carbonyl]-4-(trifluoromethoxy)-benzenesulfonamide;
- 25 Trans N-[[4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]cyclohexyl]carbonyl]-2,4,5-trifluoro-benzenesulfonamide;
- Trans 5-chloro-N-[[4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]cyclohexyl]carbonyl]-2,4-difluoro-benzenesulfonamide;
- Trans 4-chloro-N-[[4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]cyclohexyl]carbonyl]-2,5-difluoro-benzenesulfonamide;
- 30 Trans 3-chloro-N-[[4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]cyclohexyl]carbonyl]-5-fluoro-2-methyl-benzenesulfonamide;

Trans *N*-[[4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]cyclohexyl]carbonyl]-2-methylbenzenesulfonamide;

Trans *N*-[[4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]cyclohexyl]carbonyl]-2-methoxybenzenesulfonamide;

5 Trans *N*-[[4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]cyclohexyl]carbonyl]-2,6-dimethylbenzenesulfonamide;

Trans *N*-[[4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]cyclohexyl]carbonyl]-4-methylbenzenesulfonamide;

Trans *N*-[[4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]cyclohexyl]carbonyl]-10 benzenesulfonamide; or,

Trans *N*-[[4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]cyclohexyl]carbonyl]-4-(dimethylamino)- benzenesulfonamide.

A compound of formula (Id) is, for example:

15 4-(3,4-Dichlorophenoxy)-*N*-(2-methylbenzoyl)-[1,4'-bipiperidine]-1'-carboxamide;
4-(3,4-Dichlorophenoxy)-*N*-(4-methylbenzoyl)-[1,4'-bipiperidine]-1'-carboxamide;
4-(3,4-Dichlorophenoxy)-*N*-(4-chlorobenzoyl)-[1,4'-bipiperidine]-1'-carboxamide;
4-(3,4-Dichlorophenoxy)-*N*-benzoyl-[1,4'-bipiperidine]-1'-carboxamide;
4-(3,4-Dichlorophenoxy)-*N*-[(4-methylphenyl)sulfonyl]-[1,4'-bipiperidine]-1'-sulfonamide;
20 or,
4-(3,4-dichlorophenoxy)-*N*-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-[1,4'-bipiperidine]-1'-sulfonamide.

A compound of formula (Ie) is, for example:

25 [4-(3,4-dichlorophenoxy)-*N*-(phenylsulfonyl)-1,4'-bipiperidine]-1'-sulfonamide.

A compound of formula (If) is, for example:

Trans *N*-benzoyl-4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]-cyclohexanesulfonamide.

A compound of formula (Ig) is, for example:

Trans *N*-[[4-[4-(3,4-Dichlorophenoxy)-1-piperidinyl]cyclohexyl]carbonyl]-benzamide.

30 A compound of formula (Ih) is, for example:

Trans *N*-[[4-[4-(3,4-Dichlorophenoxy)-1-piperidinyl]cyclohexyl]sulfonyl]- benzenesulfonamide.


Compounds of formula (I) (for example compounds of formula (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig) or (Ih)) can be prepared by the methods described below.

A compound of formula (Ic), (If), (Ig) or (Ih) where R³ and R⁵ are both hydrogen may be converted to a compound of formula (Ic), (If), (Ig) or (Ih) where R⁵ is alkyl and R³ is hydrogen by deprotonation to a dianion, for example with 2 equivalents of LDA, followed by reaction with an alkylating agent, R⁵Hal (wherein Hal is, for example chlorine).

A compound of formula (Ic), (If), (Ig) or (Ih) where R⁵ is hydrogen and R³ is not hydrogen may be converted to a compound of formula (Ic), (If), (Ig) or (Ih) where R⁵ is alkyl and R³ is not hydrogen by deprotonation, for example with 1 equivalent of LDA, followed by reaction with an alkylating agent, R⁵Hal.


A compound of formula (I), wherein R³ is not hydrogen, can be prepared by alkylating a compound of formula (I), wherein R³ is hydrogen, with a suitable alkylating agent (for example R³-L, wherein L is a leaving group such as triflate, a halide or a diazo group) in the presence of a suitable base (such as sodium hydride) in a suitable solvent.

A compound of formula (I), wherein R³ is hydrogen, T is C(O) and Y is N, can be prepared by reacting a compound of formula (II):




with an isocyanate of formula R⁴WN=C=O in the presence of a suitable solvent at a suitable temperature (such as room temperature). Isocyanates of formula R⁴WN=C=O are commercially available or can be prepared by optional adaptation of methods described in the literature.

A compound of formula (I), wherein T is C(O), W is S(O)₂ and Y is N, can be prepared by reacting a compound of formula (II) with a compound of formula (XXII). A compound of formula (XXII):




may be prepared from a sulfonamide $R^4SO_2NHR^3$ and p-nitrophenyl chloroformate in the presence of a base, for example triethylamine and a catalyst, for example DMAP, typically at room temperature.

5 A compound of formula (II) can be prepared by deprotecting a compound of formula (III):




for example using trifluoroacetic acid in a suitable solvent (such as dichloromethane) or using a source of hydrogen chloride in a suitable solvent (such as dioxane).

10 A compound of formula (III), wherein R^2 is hydrogen, can be prepared by reacting a compound of formula (IV):




with a compound of formula (V):



in the presence of $NaBH(OAc)_3$ and acetic acid.


15 A compound of formula (III), wherein R^2 is C_{1-6} alkyl, can be prepared by reacting a compound of formula (XVII):



with a Grignard reagent of formula R^2MgHal (wherein Hal is chlorine, bromine or iodine) in a suitable solvent, such as tetrahydrofuran.


20 A compound of formula (XVII) can be prepared by reacting a compound of formula (IV) with a compound of formula (V) in the presence of titanium tetrakisopropoxide, for example in dichloroethane, followed by the addition of diethylaluminium cyanide to a solution, for example in toluene.

25 A compound of formula (I), wherein R^3 is hydrogen, T is $S(O)_2$, W is $C(O)$ and Y is N, can be prepared by reacting a compound of formula (IX):



with a compound of formula (II) in the presence of a suitable base (such as triethylamine) in a suitable solvent (such as tetrahydrofuran) at a suitable temperature (such as below -60°C). A compound of formula (IX) can be prepared by reacting an acid R^4CO_2H with 5 $ClS(O)_2N=C=O$, for example below 80°C.


Alternatively, a compound of formula (I), wherein R^3 is hydrogen, T is $S(O)_2$, W is C(O) and Y is N, can be prepared by reacting a compound of formula (XVIII):



with an acyl halide R^4COHal in the presence of a base, for example triethylamine in a 10 suitable solvent, for example dichloromethane, for example at room temperature.

A compound of formula (XVIII) may be prepared by the reaction of a compound of formula (II) with sulfamide, for example in dioxan at reflux.


A further method of preparing a compound of formula (I), wherein R^3 is hydrogen, T is $S(O)_2$, W is C(O) and Y is N, is to react a compound of formula (XIX):



15


with an acyl halide R^4COHal in the presence of a base, for example triethylamine in a suitable solvent, for example dichloromethane, for example at room temperature, followed by deprotection of the carbamate so formed, for example with trifluoroacetic acid in dichloromethane.

20 A compound of formula (XIX) can be prepared from a compound of formula (II) and a compound of formula (XX):



in a suitable solvent for example dichloromethane typically at room temperature.


A compound of formula (I) wherein T and W are both S(O)₂ and Y is N, can be prepared by reacting a compound of formula (X):



with a sulfonamide R⁴S(O)₂NHR³ in the presence of a base (such as calcium oxide), in a suitable solvent (such as DMSO) at a temperature preferably in the range 50-110°C. (For example see DE 1618439; DE 1249259; Chemical Abstracts 1967, 67, 116716a). A compound of formula (X) can be prepared by reacting a compound of formula (II) with S(O)₂Cl₂ in the presence of a suitable base (such as triethylamine).


Alternatively, a compound of formula (I) wherein T and W are both S(O)₂ and Y is N, can be prepared by reacting a compound of formula (XVIII) with a sulfonyl chloride R⁴SO₂Cl in the presence of a base, for example triethylamine, preferably with dimethylaminopyridine as catalyst in a suitable solvent, for example dichloromethane, for example at room temperature.

A compound of formula (I) wherein T is C(O), W is S(O)₂ and Y is CR⁵, can be prepared by firstly hydrolysing a compound of formula (XI):




wherein the ester is preferably a C₁₋₆ alkyl group, and reacting the product so formed with R⁴S(O)₂NHR³ in the presence of an appropriate coupling agent (such as ethyl dimethylaminopropyl carbodiimide (EDCI), with 4-dimethylaminopyridine (DMAP) or 1-hydroxybenzotriazole (HOBT)) in a suitable solvent, for example DMF.

A compound of formula (XI), wherein R² is hydrogen, can be prepared by reductively aminating a compound of formula (XII):




with a compound of formula (XIII):



A compound of formula (XI) where R² is alkyl can be prepared by amino nitrile formation between compounds of formula (XII) and (XIII) followed by displacement of the nitrile with a grignard reagent.


- 5 A compound of formula (I), wherein T and W are both C(O) and Y is CH or N, can be prepared by heating a compound of formula (XIV):



in the presence of R⁴C(OR')₂N(CH₃)₂ or R⁴C(OR')₃, wherein R' is methyl or ethyl, or (OR')₃ is (OCH₂)₃CCH₃. A compound of formula (XIV) where Y is CR⁵ can be prepared by firstly hydrolysing a compound of formula (XI) and then coupling the product so

- 10 formed with an amine R³NH₂ in the presence of an appropriate coupling agent (such as ethyl dimethylaminopropyl carbodiimide, with 4-dimethylaminopyridine or 1-hydroxybenzotriazole) in a suitable solvent, for example DMF. A compound of formula (XIV) where Y is N and R³ is H may be prepared by reaction of a compound of formula (II) with sodium cyanate in the presence of an acid, for example acetic acid. A compound 15 of formula (XIV) where Y is N and R³ is alkyl may be prepared by reaction of a compound of formula (II) with a compound of formula (XXI): R³-N=C=O; in an inert solvent, for example dichloromethane, for example at room temperature.

A compound of formula (I), wherein T is S(O)₂, W is C(O) and Y is CR⁵, can be prepared by coupling a compound of formula (XV):




20

to an acid R⁴CO₂H in the presence of an appropriate coupling agent (such as ethyl dimethylaminopropyl carbodiimide, 4-dimethylaminopyridine or HOBT) in a suitable solvent.


- A compound of formula (I), wherein T and W are both S(O)₂ and Y is CH, can be 25 prepared by coupling a compound of formula (XV) to a sulfonyl chloride R⁴S(O)₂Cl in the presence of a base and a solvent (such as dichloromethane, N,N-dimethylformamide or tetrahydrofuran).

A compound of formula (XV) can be prepared by reductively aminating a compound of formula (XVI):



- with a compound of formula (IV) to obtain a compound wherein R² is hydrogen, or
 5 aminonitrile formation followed by a Grignard reaction to obtain a compound wherein R² is alkyl.

A compound of formula (XVI) can be prepared by reacting



- 10 with CH₂=CR⁵-S(O)₂NHR³ at an elevated temperature (such as in refluxing toluene) and then hydrolysing the silyl enol ether (such as with acetic acid).

A compound of formula (I) where Y is CR⁵ and R⁵ is not hydrogen may be prepared from a compound of formula (I) where Y is CH by reaction of the dianion (R³ is H) or monoanion (R³ is alkyl) (formed with a suitable base, for example LDA) with an alkylating agent (for example R⁵-L, wherein L is a leaving group such as triflate or a halide) in a suitable solvent for example THF for example at 0° or below.
 15

Further compounds of formula (I) can be prepared by adaptation of: the routes described above, methods described in the art or the Examples recited below. The intermediates identified above are commercially available or can be prepared by using or adapting methods described in the art.

- 20 In another aspect the present invention provides processes for the preparation of compounds of formula (I) (for example a compound of formula (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig) or (Ih)).

The intermediates of formula (X), (XI), (XIV), (XV), (XVIII) and (XIX) defined herein are novel and these, and processes for their preparation, are provided as further
 25 features of the invention.

The compounds of the invention have activity as pharmaceuticals, in particular as modulators of chemokine receptor (especially CCR3) activity, and may be used in the treatment of autoimmune, inflammatory, proliferative or hyperproliferative diseases, or

immunologically-mediated diseases (including rejection of transplanted organs or tissues and Acquired Immunodeficiency Syndrome (AIDS)).

In one aspect examples of these conditions are:

- (1) (the respiratory tract) obstructive diseases of airways including: chronic obstructive pulmonary disease (COPD) (such as irreversible COPD); asthma {such as bronchial, allergic, intrinsic, extrinsic or dust asthma, particularly chronic or inveterate asthma (for example late asthma or airways hyper-responsiveness)}; bronchitis {such as eosinophilic bronchitis}; acute, allergic, atrophic rhinitis or chronic rhinitis including rhinitis caseosa, hypertrophic rhinitis, rhinitis purulenta, rhinitis sicca or rhinitis medicamentosa; membranous rhinitis including croupous, fibrinous or pseudomembranous rhinitis or scrofulous rhinitis; seasonal rhinitis including rhinitis nervosa (hay fever) or vasomotor rhinitis; sarcoidosis; farmer's lung and related diseases; nasal polypsis; fibroid lung, idiopathic interstitial pneumonia, antitussive activity, treatment of chronic cough associated with inflammatory conditions of the airways or iatrogenic induced cough;
- (2) (bone and joints) arthrides including rheumatic, infectious, autoimmune, seronegative spondyloarthropathies (such as ankylosing spondylitis, psoriatic arthritis or Reiter's disease), Behcet's disease, Sjogren's syndrome or systemic sclerosis;
- (3) (skin and eyes) psoriasis, atopic dermatitis, contact dermatitis or other eczematous dermatides, seborrhoetic dermatitis, Lichen planus, Phemphigus, bullous Phemphigus, Epidermolysis bullosa, urticaria, angiodermas, vasculitides erythemas, cutaneous eosinophilias, uveitis, Alopecia areata or vernal conjunctivitis;
- (4) (gastrointestinal tract) Coeliac disease, proctitis, eosinophilic gastro-enteritis, mastocytosis, Crohn's disease, ulcerative colitis, irritable bowel disease or food-related allergies which have effects remote from the gut (for example migraine, rhinitis or eczema);
- (5) (Allograft rejection) acute and chronic following, for example, transplantation of kidney, heart, liver, lung, bone marrow, skin or cornea; or chronic graft versus host disease; and/or
- (6) (other tissues or diseases) Alzheimer's disease, multiple sclerosis, atherosclerosis, Acquired Immunodeficiency Syndrome (AIDS), Lupus disorders (such as lupus erythematosus or systemic lupus), erythematosus, Hashimoto's thyroiditis, myasthenia gravis, type I diabetes, nephrotic syndrome, eosinophilia fascitis, hyper IgE syndrome,

leprosy (such as lepromatous leprosy), Peridental disease, Sezary syndrome, idiopathic thrombocytopenia pupura or disorders of the menstrual cycle.

The compounds of the invention are also H1 antagonists and may be used in the treatment of allergic disorders.

5 The compounds of the invention may also be used to control a sign and/or symptom of what is commonly referred to as a cold (for example a sign and/or symptom of a common cold or influenza or other associated respiratory virus infection).

10 According to a further feature of the invention there is provided a compound of formula (I) (for example a compound of formula (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig) or (Ih)), or a pharmaceutically acceptable salt thereof or a solvate thereof, for use in a method of treatment of a warm blooded animal (such as man) by therapy (including prophylaxis).

15 According to a further feature of the present invention there is provided a method for modulating chemokine receptor activity (especially CCR3 receptor activity), or antagonising H1, in a warm blooded animal, such as man, in need of such treatment, which comprises administering to said animal an effective amount of a compound of the formula (I) (for example a compound of formula (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig) or (Ih)), or a pharmaceutically acceptable salt thereof or a solvate thereof.

20 The invention also provides a compound of the formula (I) (for example a compound of formula (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig) or (Ih)), or a pharmaceutically acceptable salt thereof or a solvate thereof, for use as a medicament.

25 In another aspect the invention provides the use of a compound of formula (I) (for example a compound of formula (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig) or (Ih)), or a pharmaceutically acceptable salt thereof or a solvate thereof, in the manufacture of a medicament for use in therapy (for example modulating chemokine receptor activity (especially CCR3 receptor activity), or antagonising H1, in a warm blooded animal, such as man).

30 The invention further provides the use of a compound of formula (I) (for example a compound of formula (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig) or (Ih)), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of:

(1) (the respiratory tract) obstructive diseases of airways including: chronic obstructive pulmonary disease (COPD) (such as irreversible COPD); asthma {such as bronchial, allergic, intrinsic, extrinsic or dust asthma, particularly chronic or inveterate asthma (for example late asthma or airways hyper-responsiveness)}; bronchitis {such as

- eosinophilic bronchitis}; acute, allergic, atrophic rhinitis or chronic rhinitis including rhinitis caseosa, hypertrophic rhinitis, rhinitis purulenta, rhinitis sicca or rhinitis medicamentosa; membranous rhinitis including croupous, fibrinous or pseudomembranous rhinitis or scrofulous rhinitis; seasonal rhinitis including rhinitis nervosa (hay fever) or vasomotor rhinitis; sarcoidosis; farmer's lung and related diseases; nasal polypsis; fibroid lung, idiopathic interstitial pneumonia, antitussive activity, treatment of chronic cough associated with inflammatory conditions of the airways or iatrogenic induced cough;
- 5 (2) (bone and joints) arthrides including rheumatic, infectious, autoimmune, seronegative spondyloarthropathies (such as ankylosing spondylitis, psoriatic arthritis or Reiter's disease), Behcet's disease, Sjogren's syndrome or systemic sclerosis;
- 10 (3) (skin and eyes) psoriasis, atopic dermatitis, contact dermatitis or other eczematous dermatides, seborrhoetic dermatitis, Lichen planus, Phemphigus, bullous Phemphigus, Epidermolysis bullosa, urticaria, angiodermas, vasculitides erythemas, cutaneous eosinophilias, uveitis, Alopecia areata or vernal conjunctivitis;
- 15 (4) (gastrointestinal tract) Coeliac disease, proctitis, eosinophilic gastro-enteritis, mastocytosis, Crohn's disease, ulcerative colitis, irritable bowel disease or food-related allergies which have effects remote from the gut (for example migraine, rhinitis or eczema);
- 20 (5) (Allograft rejection) acute and chronic following, for example, transplantation of kidney, heart, liver, lung, bone marrow, skin or cornea; or chronic graft versus host disease; and/or
- (6) (other tissues or diseases) Alzheimer's disease, multiple sclerosis, atherosclerosis, Acquired Immunodeficiency Syndrome (AIDS), Lupus disorders (such as lupus erythematosus or systemic lupus), erythematosus, Hashimoto's thyroiditis, myasthenia gravis, type I diabetes, nephrotic syndrome, eosinophilia fascitis, hyper IgE syndrome, leprosy (such as lepromatous leprosy), Peridental disease, sezary syndrome, idiopathic thrombocytopenia pupura or disorders of the menstrual cycle;
- 25 in a warm blooded animal, such as man.
- 30 In a further aspect a compound of formula (I) (for example a compound of formula (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig) or (Ih)), or a pharmaceutically acceptable salt thereof, is useful in the treatment of asthma {such as bronchial, allergic, intrinsic, extrinsic or dust asthma, particularly chronic or inveterate asthma (for example late asthma or airways

hyper-responsiveness}); or rhinitis { including acute, allergic, atrophic or chronic rhinitis, such as rhinitis caseosa, hypertrophic rhinitis, rhinitis purulenta, rhinitis sicca or rhinitis medicamentosa; membranous rhinitis including croupous, fibrinous or pseudomembranous rhinitis or scrofulous rhinitis; seasonal rhinitis including rhinitis nervosa (hay fever) or 5 vasomotor rhinitis }.

In a still further aspect a compound of formula (I) (for example a compound of formula (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig) or (Ih)), or a pharmaceutically acceptable salt thereof, is useful in the treatment of asthma.

The present invention also provides the use of a compound of formula (I) (for 10 example a compound of formula (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig) or (Ih)), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of asthma or rhinitis.

The present invention further provides a method of treating a chemokine mediated disease state (especially a CCR3 mediated disease state, especially asthma) in a warm 15 blooded animal, such as man, which comprises administering to a mammal in need of such treatment an effective amount of a compound of formula (I) (for example a compound of formula (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig) or (Ih)), or a pharmaceutically acceptable salt thereof or solvate thereof.

In order to use a compound of the invention, or a pharmaceutically acceptable salt 20 thereof or solvate thereof, for the therapeutic treatment of a warm blooded animal, such as man, in particular modulating chemokine receptor (for example CCR3 receptor) activity or antagonising H1, said ingredient is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.

Therefore in another aspect the present invention provides a pharmaceutical 25 composition which comprises a compound of the formula (I) (for example a compound of formula (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig) or (Ih)), or a pharmaceutically acceptable salt thereof or a solvate thereof (active ingredient), and a pharmaceutically acceptable adjuvant, diluent or carrier. In a further aspect the present invention provides a process for the preparation of said composition which comprises mixing active ingredient with a 30 pharmaceutically acceptable adjuvant, diluent or carrier. Depending on the mode of administration, the pharmaceutical composition will preferably comprise from 0.05 to 99 %w (per cent by weight), more preferably from 0.05 to 80 %w, still more preferably from

0.10 to 70 %w, and even more preferably from 0.10 to 50 %w, of active ingredient, all percentages by weight being based on total composition.

The pharmaceutical compositions of this invention may be administered in standard manner for the disease condition that it is desired to treat, for example by topical (such as 5 to the lung and/or airways or to the skin), oral, rectal or parenteral administration. For these purposes the compounds of this invention may be formulated by means known in the art into the form of, for example, aerosols, dry powder formulations, tablets, capsules, syrups, powders, granules, aqueous or oily solutions or suspensions, (lipid) emulsions, dispersible powders, suppositories, ointments, creams, drops and sterile injectable aqueous 10 or oily solutions or suspensions.

A suitable pharmaceutical composition of this invention is one suitable for oral administration in unit dosage form, for example a tablet or capsule which contains between 0.1mg and 1g of active ingredient.

In another aspect a pharmaceutical composition of the invention is one suitable for 15 intravenous, subcutaneous or intramuscular injection.

Each patient may receive, for example, an intravenous, subcutaneous or intramuscular dose of 0.01mgkg^{-1} to 100mgkg^{-1} of the compound, preferably in the range of 0.1mgkg^{-1} to 20mgkg^{-1} of this invention, the composition being administered 1 to 4 times per day. The intravenous, subcutaneous and intramuscular dose may be given by 20 means of a bolus injection. Alternatively the intravenous dose may be given by continuous infusion over a period of time. Alternatively each patient will receive a daily oral dose which is approximately equivalent to the daily parenteral dose, the composition being administered 1 to 4 times per day.

The following illustrate representative pharmaceutical dosage forms containing the 25 compound of formula (I) (for example a compound of formula (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig) or (Ih)), or a pharmaceutically-acceptable salt thereof (hereafter Compound X), for therapeutic or prophylactic use in humans:

(a)

<u>Tablet I</u>	<u>mg/tablet</u>
Compound X	100
Lactose Ph.Eur.	179
Croscarmellose sodium	12.0
Polyvinylpyrrolidone	6
Magnesium stearate	3.0

(b)

<u>Tablet II</u>	<u>mg/tablet</u>
Compound X	50
Lactose Ph.Eur.	229
Croscarmellose sodium	12.0
Polyvinylpyrrolidone	6
Magnesium stearate	3.0

5 (c)

<u>Tablet III</u>	<u>mg/tablet</u>
Compound X	1.0
Lactose Ph.Eur.	92
Croscarmellose sodium	4.0
Polyvinylpyrrolidone	2.0
Magnesium stearate	1.0

(d)

<u>Capsule</u>	<u>mg/capsule</u>
Compound X	10
Lactose Ph.Eur.	389
Croscarmellose sodium	100
Magnesium stearate	1.0

(e)

<u>Injection I</u>	(50 mg/ml)
Compound X	5.0% w/v
Isotonic aqueous solution	to 100%

Buffers, pharmaceutically-acceptable cosolvents such as polyethylene glycol, polypropylene glycol, glycerol or ethanol or complexing agents such as hydroxy-propyl β -cyclodextrin may be used to aid formulation.

The above formulations may be obtained by conventional procedures well known in the pharmaceutical art. The tablets (a)-(c) may be enteric coated by conventional means, for example to provide a coating of cellulose acetate phthalate.

The invention will now be illustrated by the following non-limiting Examples in which, unless stated otherwise:

- (i) when given, ^1H NMR data is quoted and is in the form of delta values for major diagnostic protons, given in parts per million (ppm) relative to tetramethylsilane (TMS) as an internal standard, determined at 300MHz or 400MHz using perdeuterio DMSO-D6 (CD_3SOCD_3), methanol-D4 (CD_3OD) or CDCl_3 as the solvent unless otherwise stated;
- (ii) mass spectra (MS) were run with an electron energy of 70 electron volts in the chemical ionisation (CI) mode using a direct exposure probe; where indicated ionisation was effected by electron impact (EI) or fast atom bombardment (FAB) or electrospray (ESI); where values for m/z are given, generally only ions which indicate the parent mass are reported, and unless otherwise stated the mass ion quoted is the positive mass ion - $(\text{M}+\text{H})^+$;
- (iii) the title and sub-title compounds of the examples and methods were named using the ACD/Index name program version 4.55 from Advanced Chemistry Development, Inc;
- (iv) unless stated otherwise, reverse phase HPLC was conducted using a Symmetry, NovaPak or Xterra reverse phase silica column; and
- (v) the following abbreviations are used:

RPHPLC	reverse phase HPLC	THF	tetrahydrofuran
DEAD	diethyl-azodicarboxylate	DCM	dichloromethane
NMP	N-methylpyrrolidone	TFA	trifluoroacetic acid
CDI	N,N'-carbonyl diimidazole	m.pt.	melting point

MTBE	tert-butyl methyl ether	DMSO	dimethylsulfoxide
DMF	N,N-dimethylformamide	Ac	Acetate
HOBT	1-hydroxybenzotriazole	aq	aqueous
Boc or BOC	tert-butoxycarbonyl	RT	room temperature
HPLC	high pressure liquid chromatography	IPA	iso-propyl alcohol
EDCI	Ethyl dimethylaminopropyl carbodiimide	LDA	Lithium diisopropylamide
TMEDA	Tertamethylenelediamine	equiv.	equivalents
PYBROP™	bromo-tris-pyrrolidino-phosphonium hexafluorophosphate		

Example 1A

N-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-fluorobenzenesulfonamide (an example of a compound of formula (Ia)).

5 To a solution of 4-(3,4-dichlorophenoxy)-1,4'-bipiperidine (Method C; 0.197g) in dichloromethane (5ml) was added 4-fluorobenzenesulfonyl isocyanate (0.121g) dropwise and the reaction was stirred under nitrogen for 12 hours. The solvent was removed under reduced pressure and the resulting product was purified by RPHPLC (Waters Xterra® column), (gradient, 75:25 0.2% aq ammonia / acetonitrile to 5:95 over 10 mins) to give the title compound (60mg; MS [M+H]⁺ (APCI+) 530/532).

10 ¹H NMR (399.98 MHz, CD3OD) δ 1.50 - 1.61 (m, 2H), 2.01 - 2.24 (m, 6H), 2.64 - 2.73 (m, 2H), 3.25 - 3.43 (m, 5H), 4.42 - 4.50 (m, 2H), 4.64 - 4.71 (m, 1H), 6.95 - 6.98 (m, 1H), 7.12 - 7.16 (m, 2H), 7.21 - 7.22 (m, 1H), 7.41 - 7.44 (m, 1H), 7.90 - 7.95 (m, 2H).

15 The Examples 1B-1AV are examples of compounds of formula (Ia) and were prepared using similar methodology to that of Example 1A. Recrystallisation was required after chromatography for several Examples.

Example 2A

20 *N*-[[4-(3,4-Dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-benzenemethanesulfonamide (an example of a compound of formula (Ia)).

To a stirred solution of para-nitrophenylchloroformate (0.141g) in dichloromethane (5ml) was added dimethylaminopyridine (0.086g). After 2 minutes

benzenemethanesulfonamide (0.120g) was added followed by triethylamine (0.078g). After 30 minutes 4-(3,4-dichlorophenoxy)-1,4'-bipiperidine (Method C; 0.230g) was added and the reaction was left to stir for 2 hours. The solvent was removed under reduced pressure and the resulting product was purified by RPHPLC (Waters Xterra® column),
5 (gradient, 90:10 0.2% aq ammonia / acetonitrile to 5:95 over 6 mins) to give the title compound (202mg).

10 ^1H NMR (399.98 MHz, CD₃OD) δ 1.30 - 1.43 (m, 2H), 1.73 - 1.84 (m, 4H), 1.98 - 2.06 (m, 2H), 2.44 - 2.55 (m, 3H), 2.59 - 2.66 (m, 2H), 2.82 - 2.89 (m, 2H), 4.36 - 4.42 (m, 3H), 4.41 (s, 2H), 6.88 - 6.91 (m, 1H), 7.09 - 7.10 (m, 1H), 7.24 - 7.31 (m, 3H), 7.36 - 7.39 (m, 3H); plus 1 drop of 30% NaOD in D₂O.

ES+ 526/528

The Examples 2B-2X are examples of compounds of formula (Ia) and were prepared using similar methodology to that of Example 2A.

15

Example 3A

N-[[4-(3,4-Dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-N,4-dimethyl-benzenesulfonamide (an example of a compound of formula (Ia) where R³ is not hydrogen).

20 To a solution of N-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide (Example 1B, 0.3g) in methanol / dichloromethane (1:1, 40ml) was added (trimethylsilyl)diazomethane (2M in hexanes) (5ml) dropwise. The reaction was stirred under nitrogen for 12 hours. The solvent was removed under reduced pressure and the resulting product was purified by RPHPLC (Waters Xterra® column),
25 (gradient, 75:25 0.2% aq ammonia / acetonitrile to 5:95 over 6 mins) to give the title compound (83mg).

30 ^1H NMR (399.98 MHz, CD₃OD) δ 1.42 - 1.53 (m, 2H), 1.63 - 1.71 (m, 2H), 1.82 - 1.96 (m, 4H), 2.31 (s, 3H), 2.39 - 2.47 (m, 2H), 2.48 - 2.57 (m, 1H), 2.72 - 2.79 (m, 2H), 2.93 - 3.01 (m, 2H), 3.69 (s, 3H), 4.20 - 4.26 (m, 2H), 4.27 - 4.34 (m, 1H), 6.77 - 6.81 (m, 1H), 7.00 (d, 1H), 7.21 - 7.29 (m, 3H), 7.65 - 7.68 (m, 2H)

ES+ 540/542; m. pt. 151-153°C.

Example 4A

N-Benzoyl-4-(3,4-dichlorophenoxy)-[1,4'-bipiperidine]-1'-sulfonamide (an example of a compound of formula (Ib)).

Benzoyl sulfamoyl chloride (DE931225, (1955) Chemical Abstracts 1956, 50, 7861a; 248mg) was dissolved in THF (5ml) and cooled to -78°C. Triethylamine (170µl) was added dropwise over 160s and the solution was stirred for 25 min. 4-(3,4-Dichlorophenoxy)-1,4'-bipiperidine (Method C; 329mg) in THF (5ml) was added dropwise over 35min. Water was added then the mixture was evaporated. The residue was purified by RPHPLC (Waters Xterra® Column, eluant 0.1% aq ammonium acetate : acetonitrile 75-5 : 25-95) to give the title compound (37mg; MS [M+H]⁺ (APCI+) 512/514).

¹H NMR (399.98 MHz, DMSO) δ 1.59 (qd, 2H), 1.74 - 1.84 (m, 2H), 1.96 (d, 2H), 2.06 (d, 2H), 2.76 (t, 2H), 2.86 - 3.03 (m, 3H), 3.08 - 3.17 (m, 2H), 3.71 (d, 2H), 4.57 - 4.64 (m, 1H), 7.02 (dd, 1H), 7.32 (d, 1H), 7.37 (t, 2H), 7.45 (t, 1H), 7.53 (d, 1H), 7.92 (d, 2H).

15 Example 5A

N-Benzoyl-4-(2,4-dichloro-3-methylphenoxy)-[1,4'-bipiperidine]-1'-sulfonamide (an example of a compound of formula (Ib)).

4-(2,4-Dichloro-3-methylphenoxy)-1,4'-bipiperidine (see Method C; 240mg) was dissolved in dichloromethane (10ml). Triethylamine (107 µl) was added followed by benzoyl sulfamoyl chloride (154mg). The solution was stirred for 12h and then concentrated. The residue was purified by RPHPLC (Waters Xterra® column), (gradient, 90:10 0.2% aq ammonia / acetonitrile to 5:95 over 6 mins) to give the title compound. (70mg, MS [M+H]⁺ (APCI+) 526/528; m.pt. 223°C)

¹H NMR (399.98 MHz, CD₃OD) δ 8.00 - 8.03 (m, 2H), 7.38 - 7.43 (m, 1H), 7.31 - 7.36 (m, 2H), 7.25 (d, 1H), 6.95 (d, 1H), 4.45 - 4.52 (m, 1H), 3.80 - 3.87 (m, 2H), 2.84 - 2.92 (m, 2H), 2.73 - 2.81 (m, 2H), 2.51 - 2.58 (m, 2H), 2.44 (s, 3H), 2.38 - 2.44 (m, 1H), 1.91 - 2.03 (m, 4H), 1.80 - 1.89 (m, 2H), 1.59 - 1.70 (m, 2H); plus 1 drop of 30% NaOD in D₂O.

30 The Examples 5B-5E are examples of compounds of formula (Ia) and were prepared using similar methodology to that of Example 5A.

Example 6A

trans 4-Chloro-N-[[4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]cyclohexyl]-carbonyl]-benzenesulfonamide (an example of a compound of formula (Ic)).

Sodium 4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]-cyclohexanecarboxylate (Method F, 111mg), EDCI (99mg), HOBT (97mg), DMAP (32mg) and p-chlorobenzenesulfonamide (98mg) were combined in DMF (3ml) and stirred overnight. The solvent was evaporated and the residue was purified by RPHPLC (Waters Xterra® Column, eluant 0.1% aqueous ammonium acetate : acetonitrile 75-25 : 25-75) to give the title compound (18mg; MS [M+H]⁺ (APCI+) 545/547/549).

¹H NMR (399.98 MHz, DMSO) δ 1.23 (q, 2H), 1.35 (q, 2H), 1.74 - 1.97 (m, 7H), 2.02 - 2.11 (m, 2H), 2.88 - 3.07 (m, 4H), 3.09 - 3.21 (m, 2H), 4.56 - 4.67 (m, 1H), 7.02 (dd, 1H), 7.33 (d, 1H), 7.46 (d, 2H), 7.53 (d, 1H), 7.73 (d, 2H).

Example 7A

N-Benzoyl-4-(3,4-dichlorophenoxy)-[1,4'-bipiperidine]-1'-carboxamide (an example of a compound of formula (Id)).

4-(3,4-Dichlorophenoxy)-[1,4'-bipiperidine]-1'-carboxamide (Method H, 200mg) and triethylorthobenzoate (3ml) were heated at 150°C for 16h, then allowed to reach ambient temperature. 2M HCl (2 ml) was added and the resulting solution was stirred for 4h. The volatiles were evaporated and the residue was purified by chromatography (24:1 dichloromethane : methanol) followed by RPHPLC (Waters Xterra® column), (gradient, 75:25 0.2% aq ammonia / acetonitrile to 5:95 over 6 mins) to give the title compound (m.pt. 65-80°C; MS [M+H]⁺ (ES+) 476/478).

¹H NMR (399.98 MHz, DMSO) δ 1.42 (2H, d), 1.58 (2H, d), 1.76 (2H, d), 1.92 (2H, d), 2.39 (2H, t), 2.72 - 2.78 (2H, m), 2.81 - 2.94 (3H, m), 3.79 - 4.22 (2H, m), 4.42 (1H, t), 6.98 (1H, dd), 7.25 (1H, d), 7.44 - 7.52 (3H, m), 7.56 - 7.68 (1H, m), 7.83 - 7.92 (2H, m).

Example 8A

N-(3,4-Dichlorobenzoyl)-4-(3,4-dichlorophenoxy)-[1,4'-bipiperidine]-1'-sulfonamide (an example of a compound of formula (Ib)).

4-(3,4-Dichlorophenoxy)-[1,4'-bipiperidine]-1'-sulfonamide (Method G, 200mg), 3,4 dichlorobenzoylchloride (102mg) and triethylamine (0.07ml) were stirred together in dichloromethane (10ml) at ambient temperature for 24 hours. The solvent was evaporated and the resulting product was purified by RPHPLC (Waters Xterra® column), (gradient,

75:25 0.2% aq ammonia / acetonitrile to 5:95 over 6 mins) to give the title compound (22mg; m.pt. 166-167°C; MS APCI 580/582/584 (M+H)).

5 ¹H NMR (399.98 MHz, DMSO) δ 1.57 - 1.79 (m, 4H), 1.89 - 2.17 (m, 5H), 2.60 - 2.76 (m, 2H), 3.06 - 3.25 (m, 2H), 3.36 - 3.60 (m, 2H), 3.60 - 3.76 (m, 2H), 4.54 - 4.87 (m, 1H), 6.93 - 7.11 (m, 1H), 6.93 - 7.11 (m, 1H), 7.30 - 7.40 (m, 1H), 7.49 - 7.66 (m, 2H), 7.85 (d, 1H), 8.12 (s, 1H).

10 The Examples 8B-8F are examples of compounds of formula (Ib) and were prepared using similar methodology to that of Example 8A. Recrystallisation was required after chromatography for several Examples.

Example 9A

4-(3,4-Dichlorophenoxy)-N-(4-methylbenzoyl)-[1,4'-bipiperidine]-1'-sulfonamide (an example of a compound of formula (Ib)).

15 1,1-Dimethylethyl[4-(3,4-dichlorophenoxy)-1,4'-bipiperidin-1'-yl]sulfonylcarbamate (Method L; 400mg) and triethylamine (0.5ml) in dichloromethane (5ml) at ambient temperature were treated with 4-methylbenzoylchloride (163mg). The mixture was stirred overnight, the solvent was evaporated and the residue was dissolved in DMSO (1ml) and purified by HPLC (Waters XTerra® column) (acetonitrile/aqueous ammonia gradient) to give the title compound as a white solid (70mg).

20 MS [M+H]⁺ (APCI +) 526/528 (M+H)

25 ¹H NMR δ (DMSO) 1.51 - 1.61 (2H, m), 1.67 - 1.81 (2H, m), 1.86 - 1.96 (2H, m), 1.98 - 2.08 (2H, m), 2.33 (3H, s), 2.71 - 2.92 (5H, m), 2.98 - 3.09 (2H, m), 3.72 (2H, d), 4.52 - 4.61 (1H, m), 7.01 (1H, dd), 7.20 (2H, d), 7.30 (1H, d), 7.52 (1H, d), 7.82 (2H, d).

The Examples 9B and 9C are examples of compounds of formula (Ib) and were prepared using similar methodology to that of Example 9A.

Example 10A

30 N-[[4-(3,4-Dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methylbenzenesulfonamide, sodium salt (an example of a compound of formula (Ia)).

To N-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methylbenzenesulfonamide (0.05g) was added 0.1M sodium hydroxide (0.949ml) and methanol

(5ml). The solution was stirred until all of the starting material had dissolved. The solvent was removed under reduced pressure to give the title compound.

Mpt 201°C

MS [M+H]⁺ (APCI+) 526/528

- 5 ¹H NMR δ (CD₃OD) 1.28 - 1.42 (2H, m), 1.70 - 1.82 (4H, m), 1.96 - 2.04 (2H, m), 2.35 (3H, s), 2.43 - 2.54 (3H, m), 2.56 - 2.66 (2H, m), 2.80 - 2.87 (2H, m), 4.34 - 4.42 (3H, m), 6.87 - 6.90 (1H, m), 7.09 - 7.10 (1H, m), 7.19 - 7.23 (2H, m), 7.35 - 7.38 (1H, m), 7.75 - 7.79 (2H, m).

10 The Examples 10B-10D are examples of compounds of formula (Ia) and were prepared using similar methodology to that of Example 10A.

Example 11A

4-(3,4-Dichlorophenoxy)-N-[(1,2-dihydro-1-oxo-4-isoquinolinyl)carbonyl]-[1,4'-bipiperidine]-1'-sulfonamide (an example of a compound of formula (Ib)).

- 15 To a solution of 1,1-dimethylethyl [[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]sulfonyl]-carbamate (Method L; 0.305g) in dichloromethane was added 1,2-dihydro-1-oxo-4-isoquinolinecarbonyl chloride (0.147g, prepared from the corresponding acid by treatment with thionyl chloride at reflux) followed by triethylamine (0.097ml) and the reaction was stirred under nitrogen for 12 h. The solvent was removed under reduced pressure with the resulting product dissolved in DMSO and purified by HPLC (Waters Xterra® column), (gradient, 75% aqueous (0.2% ammonia) / acetonitrile decreasing to 5% over 10 min) to give 1,1-dimethylethyl [[4-(3,4 dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]sulfonyl][(1,2-dihydro-1-oxo-4-isoquinolinyl)carbonyl]-carbamate. (MS [M+H]⁺ (ES+) 679/681).
- 20 1,1-Dimethylethyl [[4-(3,4 dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]sulfonyl][(1,2-dihydro-1-oxo-4-isoquinolinyl)carbonyl]-carbamate was dissolved in dichloromethane (10ml) followed by the addition of trifluoroacetic acid (3ml) and allowed to stir under nitrogen for 12 h. The solvent was removed under reduced pressure and the resulting product was dissolved in DMSO and purified by HPLC (Waters Xterra® column), (gradient, 90% aqueous (0.2% ammonia) / acetonitrile decreasing to 5% over 10 min) to give the title compound (0.028g)

m.pt. 200°C

MS [M+H]⁺ (ES+) 579/581

¹H NMR (399.98 MHz) δ (CD₃OD plus 1 drop NaOD) 1.58 - 1.69 (2H, m), 1.71 - 1.81 (2H, m), 1.92 - 2.05 (4H, m), 2.37 - 2.46 (1H, m), 2.48 - 2.56 (2H, m), 2.76 - 2.90 (4H, m), 3.84 - 3.90 (2H, m), 4.35 - 4.42 (1H, m), 6.86 - 6.90 (1H, m), 7.08 (1H, d), 7.30 - 7.34 (1H, m), 7.37 (1H, d), 7.49 - 7.54 (1H, m), 8.27 - 8.31 (1H, m), 8.44 (1H, s), 8.75 (1H, d)

5

Example 12A

N-(Cyclohexylcarbonyl)-4-(3,4-dichlorophenoxy)-[1,4'-bipiperidine]-1'-sulfonamide (an example of a compound of formula (Ib)).

To a solution of 1,1-dimethylethyl[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]sulfonyl]-carbamate (Method L; 0.305g) in chloroform was added cyclohexanecarbonyl chloride (0.094ml), triethylamine (0.097ml) and dimethylaminopyridine (0.086g). The reaction mixture was heated in a CEM Discover microwave at 300W for 5 seconds reaching a temperature of 50°C; pressure developed. The solvent was removed under reduced pressure and the resulting product was dissolved in DMSO and purified by HPLC (Waters Xterra® column), (gradient, 90% aqueous (0.2% ammonia) / acetonitrile decreasing to 5% over 10 min) to give the title compound (0.176g) as a foam.

15 MS [M+H]⁺ (ES+) 518/520

¹H NMR (399.98 MHz) δ (CD₃OD) 1.10 - 1.38 (5H, m), 1.44 - 1.62 (3H, m), 1.65 - 1.76 (6H, m), 1.82 - 1.89 (2H, m), 1.90 - 1.98 (2H, m), 2.07 - 2.16 (1H, m), 2.41 - 2.57 (3H, m), 2.72 - 2.86 (4H, m), 3.74 - 3.80 (2H, m), 4.30 - 4.37 (1H, m), 6.78 - 6.81 (1H, m), 7.02 (1H, d), 7.28 (1H, d)

Example 13A

4-(3,4-Dichlorophenoxy)-*N*-(2-methyl-1-oxopropyl)-[1,4'-bipiperidine]-1'-sulfonamide (an example of a compound of formula (Ib)).

To a solution of 4-(3,4-dichlorophenoxy)-[1,4'-bipiperidine]-1'-sulfonamide (Method G; 0.408g) in dichloromethane (5ml) was added 2-methyl-propanoyl chloride (0.126ml), triethylamine (0.167ml) and dimethylaminopyridine (0.147g). The reaction was heated in a CEM Discover microwave at 50°C using 50W of power for 10 minutes. The solvent was removed under reduced pressure and the resulting product was dissolved in DMSO and purified by HPLC (Waters Xterra® column), (gradient, 90% aqueous (0.1% aqueous ammonium acetate) / acetonitrile decreasing to 5% over 10 min) to give the title compound (0.152g) as a foam.

30 MS [M+H]⁺ (ES+) 478/480

¹H NMR (399.98 MHz) δ (CD₃OD) 1.30 (6H, d), 1.75 - 1.91 (2H, m), 1.97 - 2.11 (2H, m), 2.13 - 2.32 (4H, m), 2.65 (1H, septet), 2.77 - 2.99 (3H, m), 3.02 - 3.12 (2H, m), 3.12 - 3.25 (2H, m), 4.04 - 4.15 (2H, m), 4.62 - 4.72 (1H, m), 7.09 (1H, dd), 7.31 (1H, d), 7.57 (1H, d)

Example 14A

5 4-(3,4-Dichlorophenoxy)-N-(2-phenylacetyl)-[1,4'-bipiperidine]-1'-sulfonamide (an example of a compound of formula (Ib)).

To a solution 4-(3,4-dichlorophenoxy)- [1,4'-bipiperidine]-1'-sulfonamide (Method G; 0.100g) in THF (2ml) was added potassium *tert* butoxide (0.083g) followed after 1h by phenylacetyl chloride (0.097ml). After 12h the solvent was evaporated and the resultant product was dissolved in methanol and loaded onto an Isolute® SCX cartridge which was washed with methanol and eluted with 10% ammonia in methanol. The solvent was evaporated and the residue was dissolved in DMSO and purified by HPLC (Waters Xterra® column), (gradient, 90% aqueous (0.2% ammonia) / acetonitrile decreasing to 75% over 10 min) to give the title compound (0.01g).

15 MS [M+H]⁺ (ES+) 526/528

¹H NMR (299.945 MHz) δ (CD₃OD plus 1 drop NaOD) 1.45 - 1.59 (2H, m), 1.70 - 1.89 (4H, m), 1.96 - 2.08 (2H, m), 2.23 - 2.35 (1H, m), 2.43 - 2.63 (4H, m), 2.77 - 2.88 (2H, m), 3.45 (2H, s), 3.66 - 3.75 (2H, m), 4.35 - 4.44 (1H, m), 6.88 - 6.94 (1H, m), 7.10 - 7.13 (1H, m), 7.14 - 7.30 (3H, m), 7.33 - 7.42 (3H, m)

20 Example 15A

N-[[4-(3,4-Dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-2-propanesulfonamide (an example of a compound of formula (Ia)).

To a solution 4-(3,4-dichlorophenoxy)-[1,4'-bipiperidine]-1'-carboxamide (Method H; 0.372g) in THF (5ml) was added potassium *tert* butoxide (0.337g) followed after 1h by 25 2-propanesulfonyl chloride (0.337ml). After a further 2h aqueous ammonium chloride was added and THF was evaporated to leave a precipitate which was collected. The precipitate was purified by HPLC (Waters Xterra® column), (gradient, 95% aqueous (0.2% ammonia) / acetonitrile decreasing to 50% over 10 min) to give the title compound (0.061g).

30 MS [M+H]⁺ (ES+) 478/480

¹H NMR (399.98 MHz) δ (CD₃OD plus 1 drop NaOD) 1.19 (6H, d), 1.23 - 1.37 (2H, m), 1.62 - 1.70 (2H, m), 1.71 - 1.78 (2H, m), 1.88 - 1.96 (2H, m), 2.34 - 2.47 (3H, m), 2.48 -

2.60 (2H, m), 2.72 - 2.80 (2H, m), 3.38 - 3.46 (1H, m), 4.27 - 4.37 (3H, m), 6.79 (1H, dd),
6.99 (1H, d), 7.28 (1H, d)

Example 16A

5 4-(3,4-Dichlorophenoxy)-N-[(4-methylphenyl)sulfonyl]-[1,4'-bipiperidine]-1'-sulfonamide sodium salt (an example of a compound of formula (Ie)).
4-(3,4-Dichlorophenoxy)-[1,4'-bipiperidine]-1'-sulfonamide (Method L; 582mg), toluenesulfonyl chloride (380mg) and DMAP (180mg) were combined and dissolved in dichloromethane (10ml). Triethylamine (0.3ml) was added, followed after 35min by a second portion of triethylamine (0.3ml). The solution was stirred for 21h and then 10 concentrated. The residue was triturated with methanol and then THF to give a solid (0.65g). A portion of the product (0.34g) was dissolved in warm DMSO (30ml). To this solution was added aqueous sodium hydroxide (1M, 6ml) followed by water (200ml). The solution was allowed to cool overnight and the title compound was collected (175mg).

m. pt. 242-243°C

15 MS [M+H]⁺ (ES+) 562/564

¹H NMR (399.98 MHz) δ_(DMSO) 1.27 (2H, qd), 1.51 - 1.60 (2H, m), 1.65 (2H, d), 1.88 - 1.94 (2H, m), 2.23 (1H, tt), 2.31 (3H, s), 2.32 - 2.43 (4H, m), 2.68 - 2.75 (2H, m), 3.33 - 3.38 (2H, m), 4.37 - 4.43 (1H, m), 6.98 (1H, dd), 7.18 (2H, d), 7.25 (1H, d), 7.48 (1H, d), 7.60 (2H, d)

20 Example 16B (an example of a compound of formula (Ie)) was prepared using similar methodology to that of Example 16A and recrystallisation was required after chromatography.

Example	Compound	MS [M+H] ⁺ (ES+)	¹ H NMR δ	m.pt. °C
1B Recrystallisation solvent DMSO	N-[4-(3,4-Dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl-4-methylbenzenesulfonamide	526/528	(CD ₃ OD) 1.18 - 1.30 (m, 2H), 1.62 - 1.74 (m, 4H), 1.87 - 1.95 (m, 2H), 2.26 (s, 3H), 2.32 - 2.43 (m, 3H), 2.48 - 2.57 (m, 2H), 2.70 - 2.76 (m, 2H), 4.25 - 4.33 (m, 3H), 6.77 - 6.81 (m, 1H), 6.98 - 7.00 (m, 1H), 7.11 - 7.15 (m, 2H), 7.28 (d, 1H), 7.65 - 7.68 (m, 2H); 0.7ml of CD ₃ OD plus 1 drop of NaOD (30% in D ₂ O)	228.1-228.6
1C	N-[4-(2,4-Dichloro-3-methylphenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl-4-methylbenzenesulfonamide	540/542	(CD ₃ OD) 1.50 - 1.61 (m, 2H), 1.97 - 2.04 (m, 2H), 2.08 - 2.21 (m, 4H), 2.36 (s, 3H), 2.47 (s, 3H), 2.64 - 2.73 (m, 2H), 3.22 - 3.40 (m, 5H), 4.40 - 4.49 (m, 2H), 4.70 - 4.76 (m, 1H), 7.01 - 7.03 (m, 1H), 7.22 - 7.24 (m, 2H), 7.27 - 7.29 (m, 1H), 7.76 - 7.79 (m, 2H)	
1D Recrystallisation solvent methanol	4-Chloro-N-[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl-4-methylbenzenesulfonamide	546/548/ 550	(CD ₃ OD) 1.18 - 1.28 (m, 2H), 1.61 - 1.75 (m, 4H), 1.87 - 1.94 (m, 2H), 2.33 - 2.43 (m, 3H), 2.47 - 2.58 (m, 2H), 2.70 - 2.77 (m, 2H), 4.25 - 4.32 (m, 3H), 6.78 - 6.80 (m, 1H), 6.99 - 7.00 (m, 1H), 7.27 - 7.34 (m, 3H), 7.74 - 7.77 (m, 2H); 0.7ml of CD ₃ OD plus 1 drop of NaOD (30% in D ₂ O)	

1E	<i>N</i> -[[4-(3,4-Dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-2-methylbenzenesulfonamide	526/528	(CD ₃ OD) 1.50 - 1.61 (m, 2H), 2.01 - 2.11 (m, 4H), 2.12 - 2.24 (m, 2H), 2.63 - 2.73 (m, 2H), 2.64 (s, 3H), 3.25 - 3.43 (m, 5H), 4.43 - 4.52 (m, 2H), 4.63 - 4.69 (m, 1H), 6.94 - 6.98 (m, 1H), 7.20 - 7.25 (m, 3H), 7.30 - 7.35 (m, 1H), 7.41 - 7.44 (m, 1H), 7.95 - 7.99 (m, 1H)	160-161
1F	<i>N</i> -[[4-(3,4-Dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-benzenesulfonamide	512/514	(CD ₃ OD) 1.17 - 1.33 (m, 2H), 1.59 - 1.76 (m, 4H), 1.86 - 1.96 (m, 2H), 2.31 - 2.45 (m, 3H), 2.47 - 2.59 (m, 2H), 2.69 - 2.78 (m, 2H), 4.24 - 4.34 (m, 3H), 6.77 - 6.81 (m, 1H), 6.98 - 7.00 (m, 1H), 7.26 - 7.36 (m, 4H), 7.76 - 7.81 (m, 2H); plus 1 drop of 30% NaOD	207-214
1G	<i>N</i> -[[4-(4-Chloro-2-methylphenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methylbenzenesulfonamide	506/508	(CD ₃ OD) 1.49 - 1.61 (m, 2H), 1.99 - 2.05 (m, 2H), 2.06 - 2.14 (m, 2H), 2.15 - 2.23 (m, 2H), 2.22 (s, 3H), 2.36 (s, 3H), 2.64 - 2.73 (m, 2H), 3.22 - 3.39 (m, 5H), 4.39 - 4.48 (m, 2H), 4.60 - 4.66 (m, 1H), 6.91 - 6.95 (m, 1H), 7.10 - 7.17 (m, 2H), 7.21 - 7.25 (m, 2H), 7.75 - 7.80 (m, 2H)	

1H	<i>N</i> -[4-(3,4-Dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-2-chlorobenzenesulfonamide	546/548	(CD ₃ OD) 1.17 - 1.36 (m, 2H), 1.59 - 1.76 (m, 4H), 1.85 - 1.97 (m, 2H), 2.31 - 2.45 (m, 3H), 2.47 - 2.59 (m, 2H), 2.68 - 2.78 (m, 2H), 4.24 - 4.37 (m, 3H), 6.76 - 6.81 (m, 1H), 6.98 - 7.00 (m, 1H), 7.21 - 7.36 (m, 4H), 7.94 - 8.01 (m, 1H); plus 1 drop of 30% NaOD in D ₂ O
1I	<i>N</i> -[4-(2,4-Dichloro-3-methylphenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-chlorobenzenesulfonamide	560/562/564	(CD ₃ OD) 1.19 - 1.31 (m, 2H), 1.68 - 1.79 (m, 4H), 1.84 - 1.93 (m, 2H), 2.35 (s, 3H), 2.37 - 2.46 (m, 3H), 2.48 - 2.58 (m, 2H), 2.71 - 2.79 (m, 2H), 4.24 - 4.34 (m, 2H), 4.35 - 4.41 (m, 1H), 6.83 - 6.87 (m, 1H), 7.14 - 7.17 (m, 1H), 7.30 - 7.33 (m, 2H), 7.74 - 7.77 (m, 2H) 1 drop of 30% NaOD added in D ₂ O
1J	<i>N</i> -[4-[3,4-dichlorophenyl)methyl][1,4'-bipiperidin]-1'-yl]carbonyl]-4-methylbenzenesulfonamide	524/526	(CDCl ₃) 7.79 (3H, d), 7.32 (1H, d), 7.20 (2H, d), 7.13 (1H, d), 6.89 (1H, dd), 4.56 (2H, s), 3.55 (2H, d), 3.07 (1H, s), 2.62 (4H, s), 2.35 (5H, s), 2.02 (2H, d), 1.66 (7H, d)

1K	2-Chloro-N-[4-[(3,4-dichlorophenyl)methyl][1,4'-bipiperidin]-1'-y]carbonylbenzenesulfonamide	544/546/ 548	(CD ₃ OD) 8.07 (1H, dd), 7.47 - 7.31 (5H, m), 7.09 (1H, dd), 2.91 (2H, d), 2.91 (2H, d), 2.59 (2H, t), 2.52 (2H, d), 2.43 - 2.34 (1H, m), 2.15 (2H, t), 1.77 (2H, d), 1.62 (2H, d), 1.57 - 1.44 (1H, m), 1.29 (4H, d)	212-239
1L	4-Chloro-N-[4-[(3,4-dichlorophenyl)methyl][1,4'-bipiperidin]-1'-y]carbonylbenzenesulfonamide	542/544/ 546	(CD ₃ OD) 1.18 - 1.39 (4H, m), 1.46 - 1.59 (1H, m), 1.62 (2H, d), 1.77 (2H, d), 2.15 (2H, dd), 2.34 - 2.44 (1H, m), 2.49 - 2.65 (4H, m), 2.90 (2H, d), 4.34 (2H, s), 7.09 (1H, dd), 7.32 (1H, d), 7.38 - 7.43 (3H, m), 7.84 (2H, dt)	164-184
1M	N-[4-[(5-Chloro-2-pyridinyl)oxy][1,4'-bipiperidin]-1'-y]carbonyl-4-methylbenzenesulfonamide	493/495	(DMSO) 8.20 (1H, d), 7.81 (1H, dd), 7.67 (2H, d), 7.23 (2H, d), 6.87 (1H, d), 5.09 - 5.01 (1H, m), 4.16 (2H, d), 3.13 - 3.00 (1H, m), 2.94 - 2.77 (1H, m), 2.62 - 2.53 (5H, m), 2.33 (3H, s), 2.13 - 2.02 (2H, m), 1.85 - 1.75 (4H, m), 1.37 - 1.23 (2H, m)	

IN	2-Chloro-N-[[4-(2-chloro-4-fluorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-benzenesulfonamide	530/532	(CD ₃ OD) 1.44 - 1.56 (m, 2H), 1.90 - 1.97 (m, 2H), 1.98 - 2.15 (m, 4H), 2.56 - 2.66 (m, 2H), 3.20 - 3.40 (m, 5H), 4.35 - 4.46 (m, 2H), 4.54 - 4.64 (m, 1H), 6.93 - 6.99 (m, 1H), 7.07 - 7.11 (m, 1H), 7.14 - 7.17 (m, 1H), 7.24 - 7.35 (m, 3H), 7.99 - 8.02 (m, 1H)	
1O	N-[[4-(2-Chloro-4-fluorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide	510/512	(CD ₃ OD) 1.27 - 1.37 (m, 2H), 1.78 - 1.87 (m, 4H), 1.93 - 2.02 (m, 2H), 2.35 (s, 3H), 2.42 - 2.53 (m, 3H), 2.57 - 2.67 (m, 2H), 2.82 - 2.89 (m, 2H), 4.34 - 4.45 (m, 3H), 6.97 - 7.03 (m, 1H), 7.08 - 7.12 (m, 1H), 7.16 - 7.20 (m, 1H), 7.20 - 7.24 (m, 2H), 7.74 - 7.77 (m, 2H) 0.7ml of CD3OD plus 1 drop of NaOD (30% in D2O)	221-222
1P	N-[[4-(2,4-Dichloro-3-methylphenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-benzenesulfonamide	ES+ 526/ 528	(CD ₃ OD) 1.42 - 1.53 (m, 2H), 1.89 - 1.95 (m, 2H), 2.01 - 2.09 (m, 4H), 2.37 (s, 3H), 2.55 - 2.65 (m, 2H), 3.17 - 3.34 (m, 5H), 4.32 - 4.41 (m, 2H), 4.61 - 4.67 (m, 1H), 6.91 - 6.94 (m, 1H), 7.20 - 7.22 (m, 1H), 7.30 - 7.37 (m, 3H), 7.78 - 7.82 (m, 2H)	

1Q	N-[4-(4-chlorophenoxy)[1,4'-bipiperidin]-1'-y]carbonyl]-4-methylbenzenesulfonamide	492/494	(CD ₃ OD plus 1 drop NaOD) 1.27 - 1.39 (2H, m), 1.70 - 1.84 (4H, m), 1.96 - 2.04 (2H, m), 2.36 (3H, s), 2.40 - 2.51 (3H, m), 2.56 - 2.67 (2H, m), 2.79 - 2.87 (2H, m), 4.31 - 4.42 (3H, m), 6.89 (2H, d), 7.20 - 7.24 (4H, m), 7.76 (2H, d)	237-238
1R	N-[4-(2,4-dichloro-3-methylphenoxy)[1,4'-bipiperidin]-1'-y]carbonyl]-2-methylbenzenesulfonamide	540/542	(CD ₃ OD plus 1 drop NaOD) 1.27 - 1.41 (2H, m), 1.78 - 1.88 (4H, m), 1.93 - 2.02 (2H, m), 2.44 - 2.55 (3H, m), 2.44 (3H, s), 2.57 - 2.67 (2H, m), 2.66 (3H, s), 2.81 - 2.89 (2H, m), 4.35 - 4.51 (3H, m), 6.95 (1H, d), 7.19 - 7.34 (4H, m), 7.94 - 7.97 (1H, m)	
1S	N-[4-(2,4-dichloro-3-fluorophenoxy)[1,4'-bipiperidin]-1'-y]carbonyl]-4-methylbenzenesulfonamide		(CDCl ₃) 1.61 (2H, q), 2.07 (4H, t), 2.28 (2H, t), 2.38 (3H, s), 2.70 (2H, t), 2.93 - 3.05 (1H, m), 3.12 (2H, t), 3.18 - 3.28 (2H, m), 4.45 (2H, d), 4.60 - 4.67 (1H, m), 6.79 (1H, dd), 7.24 (2H, d), 7.30 (1H, d), 7.80 (2H, d)	

1T	N-[4-(4-chloro-2-methylphenoxy)][1,4'-bipiperidin]-1'-y]carbonyl]-2-methylbenzenesulfonamide	506/508	(CD ₃ OD) 1.40 - 1.55 (3H, m), 1.91 - 2.03 (6H, m), 2.13 (3H, s), 2.56 (3H, s), 2.56 - 2.64 (3H, m), 3.23 - 3.30 (3H, m), 4.34 - 4.44 (2H, m), 4.50 - 4.56 (1H, m), 6.80 (1H, d), 7.00 - 7.07 (2H, m), 7.11 - 7.16 (2H, m), 7.20 - 7.25 (1H, m), 7.84 - 7.88 (1H, m)	161
1U	2-chloro-N-[4-(4-chloro-2-methylphenoxy)][1,4'-bipiperidin]-1'-y]carbonyl]-2-methylbenzenesulfonamide	526/528	(CD ₃ OD) 1.51 - 1.64 (3H, m), 2.05 (5H, d), 2.71 (3H, t), 3.33 - 3.40 (4H, m), 4.44 - 4.56 (3H, m), 4.61 - 4.68 (2H, m), 6.94 (1H, d), 7.12 (1H, dd), 7.34 (1H, d), 7.35 (1H, d), 7.38 (1H, dd), 7.42 - 7.45 (1H, m), 8.09 (1H, dd)	164
1V	4-chloro-N-[4-(4-chloro-2-methylphenoxy)][1,4'-bipiperidin]-1'-y]carbonyl]-2-methylbenzenesulfonamide	526/528	(CD ₃ OD) 1.68 - 1.82 (2H, m), 2.09 - 2.15 (4H, m), 2.17 - 2.21 (3H, m), 2.37 - 2.48 (2H, m), 2.59 - 2.71 (2H, m), 2.99 - 3.14 (3H, m), 3.40 - 3.52 (2H, m), 4.49 - 4.63 (3H, m), 6.68 (1H, d), 7.07 - 7.16 (2H, m), 7.36 (2H, d), 7.88 (2H, d)	160

1W	N-[4-(2,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-y]carbonyl]-4-methylbenzenesulfonamide	526/528	(CD ₃ OD plus 1 drop NaOD) 1.27 - 1.40 (2H, m), 1.77 - 1.88 (4H, m), 1.94 - 2.03 (2H, m), 2.35 (3H, s), 2.42 - 2.55 (3H, m), 2.56 - 2.68 (2H, m), 2.80 - 2.88 (2H, m), 4.33 - 4.44 (2H, m), 4.45 - 4.52 (1H, m), 7.08 (1H, d), 7.21 - 7.25 (3H, m), 7.38 (1H, d), 7.76 (2H, d)	
1X	N-[4-(3-chlorophenoxy)[1,4'-bipiperidin]-1'-y]carbonyl]-4-methylbenzenesulfonamide	492/494	(CD ₃ OD plus 1 drop NaOD) 1.30 (2H, q), 1.71 - 1.83 (4H, m), 1.94 - 2.04 (2H, m), 2.34 (3H, s), 2.40 - 2.50 (3H, m), 2.56 - 2.68 (2H, m), 2.75 - 2.83 (2H, m), 4.32 - 4.43 (3H, m), 6.81 - 6.89 (3H, m), 7.22 (1H, t), 7.22 (2H, d), 7.76 (2H, d)	172-178
1Y	2-chloro-N-[4-(3-chlorophenoxy)[1,4'-bipiperidin]-1'-y]carbonyl]-4-methylbenzenesulfonamide	512/514	(CD ₃ OD plus 1 drop NaOD) 1.30 - 1.43 (2H, m), 1.72 - 1.86 (4H, m), 1.97 - 2.03 (2H, m), 2.42 - 2.53 (3H, m), 2.58 - 2.67 (2H, m), 2.80 - 2.87 (2H, m), 4.35 - 4.46 (3H, m), 6.85 - 6.94 (3H, m), 7.22 (1H, t), 7.32 - 7.46 (3H, m), 8.08 (1H, dd)	180-186

1Z	N-[4-(3-chlorophenoxy)[1,4'-bipiperidin]-1'-y]carbonyl]-benzenesulfonamide	478/480	(CD ₃ OD plus 1 drop NaOD) 1.26 - 1.41 (2H, m), 1.69 - 1.85 (4H, m), 1.95 - 2.04 (2H, m), 2.41 - 2.53 (3H, m), 2.57 - 2.68 (2H, m), 2.79 - 2.88 (2H, m), 4.34 - 4.46 (3H, m), 6.83 - 6.94 (3H, m), 7.22 (1H, dt), 7.39 - 7.46 (3H, m), 7.87-7.89 (2H, m)	197-206
1AA	2-chloro-N-[4-(3-chloro-2-methyl[phenoxy)[1,4'-bipiperidin]-1'-y]carbonyl]-benzenesulfonamide	526/528	(CD ₃ OD plus 1 drop NaOD) 1.32 - 1.43 (2H, m), 1.76 - 1.86 (4H, m), 1.95 - 2.04 (2H, m), 2.25 (3H, s), 2.46 - 2.55 (3H, m), 2.59 - 2.69 (2H, m), 2.79 - 2.87 (2H, m), 4.35 - 4.48 (3H, m), 6.88 (1H, d), 6.93 (1H, d), 7.08 (1H, t), 7.32 - 7.45 (3H, m), 8.08 (1H, dd)	223-234
1AB	N-[4-(2-chloro-4-fluorophenoxy)[1,4'-bipiperidin]-1'-y]carbonyl]-2-methyl-benzenesulfonamide	510/512	(DMSO) 1.17 - 1.46 (2H, m), 1.65 - 2.16 (8H, m), 2.57 (3H, s), 2.77 - 3.85 (6H, m), 4.12 - 4.32 (2H, m), 7.12 - 7.34 (5H, m), 7.46 (1H, dd), 7.78 (1H, d)	164-165

1AC	2-chloro-N-[4-(2,4-dichloro-3-fluorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-benzenesulfonamide	564/566/568	(DMSO) 1.20 - 1.50 (2H, m), 1.69 - 2.30 (7H, m), 2.88 - 3.60 (8H, m), 4.17 - 4.40 (1H, m), 7.10 - 7.27 (1H, m), 7.27 - 7.44 (3H, m), 7.57 (1H, t), 7.83 - 7.98 (1H, m)	172-173
1AD	4-chloro-N-[4-(2,4-dichloro-3-fluorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-benzenesulfonamide	564/566/568	(DMSO) 1.21 - 1.48 (2H, m), 1.64 - 2.25 (6H, m), 2.88 - 3.40 (9H, m), 4.10 - 4.41 (1H, m), 7.18 (1H, dd), 7.43 (2H, d), 7.56 (1H, t), 7.67 - 7.85 (2H, d)	167-168
1AE	N-[4-(2,4-dichloro-3-fluorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-2-methyl-benzenesulfonamide	544/546	(DMSO) 1.21 - 1.42 (2H, m), 1.62 - 2.17 (6H, m), 2.55 (3H, s), 2.75 - 3.24 (7H, m), 4.09 - 4.35 (2H, m), 4.60 - 4.87 (1H, m), 7.13 - 7.24 (3H, m), 7.28 - 7.37 (1H, m), 7.55 (1H, t), 7.80 (1H, d)	151-152

1AF	2-chloro-N-[4-(4-chlorophenoxy)[1,4'-bipiperidin]-1'-y]carbonyl]-benzenesulfonamide	512/514	(DMSO) 1.23 - 1.53 (2H, m), 1.62 - 2.39 (7H, m), 2.92 - 3.68 (6H, m), 4.13 - 4.44 (2H, m), 4.44 - 4.91 (1H, m), 6.95 - 7.17 (2H, m), 7.30 - 7.45 (5H, m), 7.82 - 8.01 (1H, m)	182-183
1AH	4-chloro-N-[4-(4-chlorophenoxy)[1,4'-bipiperidin]-1'-y]carbonyl]-benzenesulfonamide	512/514	(DMSO) 1.11 - 1.37 (3H, m), 1.47 - 2.20 (7H, m), 2.55 - 3.24 (6H, m), 4.04 - 4.64 (2H, m), 7.00 (2H, d), 7.32 (2H, d), 7.39 (2H, dt), 7.72 (2H, dt)	249-250
1AI	N-[4-(4-chlorophenoxy)[1,4'-bipiperidin]-1'-y]carbonyl]-2-methyl-benzenesulfonamide	492/494	(DMSO) 1.14 - 1.43 (2H, m), 1.64 - 2.16 (6H, m), 2.55 (3H, s), 2.77 - 3.52 (7H, m), 4.15 - 4.32 (2H, m), 4.42 - 4.71 (1H, m), 7.02 (2H, d), 7.12 - 7.25 (2H, m), 7.25 - 7.39 (3H, m), 7.78 (1H, d)	153-154

1A]	2-chloro-N-[4-(2,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-y]carbonyl]-benzenesulfonamide	546/548/550	(DMSO) 1.22 - 1.49 (2H, m), 1.65 - 2.27 (6H, m), 2.94 - 3.62 (8H, m), 4.15 - 4.43 (2H, m), 7.20 - 7.47 (5H, m), 7.62 (1H, s), 7.83 - 8.02 (1H, m)	162-163
1AK	4-chloro-N-[4-(2,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-y]carbonyl]-benzenesulfonamide	546/548/550	(DMSO) 1.14 - 1.50 (2H, m), 1.66 - 2.23 (6H, m), 2.83 - 3.48 (9H, m), 4.19 - 4.31 (1H, m), 7.29 (2H, d), 7.36 - 7.45 (2H, m), 7.61 (1H, d) 7.68 - 7.88 (2H, m)	169-170
1AL	N-[4-(2,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-y]carbonyl]-2-methyl-benzenesulfonamide	526/528	(CD ₃ OD) 1.73 - 2.06 (6H, m), 2.42 - 2.63 (6H, m), 2.66 (3H, s), 2.78 - 2.92 (3H, m), 4.35 - 4.54 (3H, m), 7.08 (1H, d), 7.19 - 7.26 (3H, m), 7.28 - 7.34 (1H, m), 7.39 (1H, d), 7.91 - 8.02 (1H, m)	165-166

1AM	2-chloro-N-[4-(3,4-difluorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-benzenesulfonamide	514/516	(DMSO) 1.28 - 1.47 (2H, m), 1.59 - 2.40 (6H, m), 2.90 - 3.60 (7H, m), 4.16 - 4.42 (2H, m), 4.44 - 4.92 (1H, m), 6.77 - 6.92 (1H, m), 7.07 - 7.45 (5H, m), 7.81 - 7.98 (1H, m)	165-166
1AN	N-[4-(3,4-difluorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-2-methyl-benzenesulfonamide	494	(DMSO) 1.20 - 1.48 (2H, m), 1.56 - 2.27 (6H, m), 2.55 (3H, s), 2.86 - 3.57 (8H, m), 4.04 - 4.64 (2H, m), 6.77 - 6.90 (1H, m), 7.11 - 7.46 (5H, m), 7.75 - 7.88 (1H, d)	147-148
1AO	N-[4-(3,4-difluorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide	494	(DMSO) 1.18 - 1.44 (2H, m), 1.57 - 2.20 (6H, m), 2.53 (3H, s), 2.63 - 3.53 (7H, m), 4.11 - 4.23 (2H, m), 4.38 - 4.67 (1H, m), 6.78 - 6.85 (1H, m), 7.09 - 7.18 (1H, m), 7.22 (2H, d), 7.34 (1H, dd), 7.67 (2H, d)	140-141

1AP	N-[4-(3-chloro-2-methylphenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methylbenzenesulfonamide	506/508	(CD ₃ OD plus 1 drop NaOD) 1.23 - 1.36 (2H, m), 1.80 (4H, d), 1.93 - 2.03 (2H, m), 2.22 (3H, s), 2.32 (3H, s), 2.42 - 2.52 (3H, m), 2.58 - 2.67 (2H, m), 2.73 - 2.80 (2H, m), 4.33 - 4.45 (3H, m), 6.84 (1H, d), 6.90 (1H, d), 7.08 (1H, t), 7.21 (2H, d), 7.76 (2H, d)	206-210
1AQ	N-[4-(3-chloro-2-methylphenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methylbenzenesulfonamide	492/494	(CD ₃ OD plus 1 drop NaOD) 1.28 - 1.45 (2H, m), 1.79 - 1.89 (4H, m), 1.97 - 2.08 (2H, m), 2.26 (3H, s), 2.42 - 2.70 (5H, m), 2.79 - 2.89 (2H, m), 4.37 - 4.48 (3H, m), 6.89 (1H, d), 6.94 (1H, d), 7.09 (1H, td), 7.39 - 7.47 (3H, m), 7.87 - 7.92 (2H, m)	173-186
1AR	3-chloro-N-[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methylbenzenesulfonamide	546/548/550	(CD ₃ OD) 1.23 - 1.44 (4H, m), 1.70 - 1.87 (4H, m), 1.99 (2H, s), 2.49 (2H, d), 2.56 - 2.70 (1H, m), 2.83 (2H, s), 4.38 (3H, s), 6.88 (1H, dd), 7.09 (1H, d), 7.33 - 7.45 (3H, m), 7.79 (1H, dd), 7.88 (1H, d)	145-155

1AS	N-[4-(2,4-dichloro-3-methylphenoxy)[1,4'-bipiperidin]-1'-y]carbonyl]-4-fluorobenzenesulfonamide	544/546	(CD ₃ OD) 1.58 (2H, td), 2.00 - 2.08 (2H, m), 2.16 (4H, d), 2.46 (3H, s), 2.70 (2H, t), 3.32 - 3.46 (4H, m), 4.46 (2H, d), 4.58 (1H, s), 4.74 (1H, s), 7.03 (1H, d), 7.14 (2H, t), 7.30 (1H, d), 7.88 - 7.94 (2H, m)	147-169
1AT	2-chloro-N-[4-(2,4-dichloro-3-methylphenoxy)[1,4'-bipiperidin]-1'-y]carbonyl]-benzenesulfonamide	560/562/564	(CD ₃ OD plus 1 drop NaOD) 1.28 - 1.45 (2H, m), 1.77 - 1.88 (4H, m), 1.94 - 2.02 (2H, m), 2.45 (3H, s), 2.46 - 2.56 (3H, m), 2.58 - 2.68 (2H, m), 2.82 - 2.89 (2H, m), 4.36 - 4.51 (3H, m), 6.95 (1H, d), 7.25 (1H, d), 7.32 - 7.44 (3H, m), 8.08 - 8.11 (1H, m)	216
1AU	N-[4-(3,4-dichloro-2-methylphenoxy)[1,4'-bipiperidin]-1'-y]carbonyl]-4-methylbenzenesulfonamide	540/2	(CD ₃ OD plus 1 drop NaOD) 1.28 - 1.41 (2H, m), 1.76 - 1.85 (4H, m), 1.96 - 2.05 (2H, m), 2.31 (3H, s), 2.35 (3H, s), 2.43 - 2.56 (3H, m), 2.57 - 2.67 (2H, m), 2.77 - 2.85 (2H, m), 4.34 - 4.47 (3H, m), 6.91 (1H, d), 7.22 (2H, d), 7.27 (1H, d), 7.76 (2H, d)	195-200

1AV	2-chloro-N-[4-(3,4-dichloro-2-methylphenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl-benzenesulfonamide	560/562/564	171
2B	3-Cyano-N-[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl-benzenesulfonamide	537/539	(CD ₃ OD) 1.27 - 1.40 (m, 2H), 1.70 - 1.85 (m, 4H), 1.96 - 2.04 (m, 2H), 2.43 - 2.53 (m, 3H), 2.56 - 2.69 (m, 2H), 2.79 - 2.86 (m, 2H), 4.33 - 4.42 (m, 3H), 6.86 - 6.90 (m, 1H), 7.07 - 7.09 (m, 1H), 7.36 - 7.39 (m, 1H), 7.59 - 7.64 (m, 1H), 7.78 - 7.81 (m, 1H), 8.13 - 8.16 (m, 1H), 8.21 - 8.22 (m, 1H); plus 1 drop of NaOD, 30% in D ₂ O
2C	N-[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl-3-(trifluoromethyl)-benzenesulfonamide	580/582	(CD ₃ OD) 1.40 - 1.53 (m, 2H), 1.91 - 1.97 (m, 4H), 2.01 - 2.16 (m, 2H), 2.55 - 2.65 (m, 2H), 3.17 - 3.36 (m, 5H), 4.33 - 4.42 (m, 2H), 4.55 - 4.62 (m, 1H), 6.84 - 6.89 (m, 1H), 7.11 - 7.13 (m, 1H), 7.33 (d, 1H), 7.51 - 7.56 (m, 1H), 7.63 - 7.67 (m, 1H), 8.02 - 8.05 (m, 1H), 8.09 (s, 1H)

2D	N-[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methoxybenzenesulfonamide	542/544	(CD ₃ OD plus 1 drop NaOD) 1.28 - 1.40 (2H, m), 1.70 - 1.84 (4H, m), 1.96 - 2.04 (2H, m), 2.42 - 2.53 (3H, m), 2.56 - 2.66 (2H, m), 2.78 - 2.86 (2H, m), 3.81 (3H, s), 4.34 - 4.42 (3H, m), 6.87 - 6.90 (1H, m), 6.91 - 6.95 (2H, m), 7.09 (1H, d), 7.37 (1H, d), 7.79 - 7.83 (2H, m)	
2E	N-[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-2,4,5-trifluorobenzenesulfonamide	566/568	(CD ₃ OD plus 1 drop NaOD) 1.28 - 1.43 (2H, m), 1.70 - 1.85 (4H, m), 1.96 - 2.05 (2H, m), 2.43 - 2.54 (3H, m), 2.57 - 2.69 (2H, m), 2.80 - 2.88 (2H, m), 4.33 - 4.43 (3H, m), 6.88 (1H, dd), 7.09 (1H, d), 7.20 (1H, ddd), 7.37 (1H, d), 7.79 (1H, ddd)	223-228
2F	N-[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-2,5-difluorobenzenesulfonamide	548/550	(CD ₃ OD) 1.51 - 1.63 (2H, m), 2.00 - 2.09 (4H, m), 2.09 - 2.27 (3H, m), 2.65 - 2.76 (2H, m), 3.32 - 3.46 (4H, m), 4.41 - 4.54 (2H, m), 4.63 - 4.73 (1H, m), 6.97 (1H, dd), 7.12 - 7.24 (3H, m), 7.43 (1H, d), 7.59 - 7.63 (1H, m)	212-222

2G	N-[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-y]carbonyl-4-(dimethylamino)benzenesulfonamide	555/557	(CD ₃ OD plus 1 drop NaOD) 1.25 - 1.34 (2H, m), 1.66 - 1.77 (4H, m), 1.94 - 2.02 (2H, m), 2.39 - 2.47 (3H, m), 2.52 - 2.61 (2H, m), 2.75 - 2.83 (2H, m), 2.97 (6H, s), 4.31 - 4.43 (3H, m), 6.67 - 6.70 (2H, m), 6.93 (1H, dd), 7.14 (1H, d), 7.42 (1H, d), 7.64 - 7.68 (2H, m)	194-196
2H	N-[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-y]carbonyl-2-methoxybenzenesulfonamide	542/544	(CD ₃ OD) 1.28 - 1.41 (2H, m), 1.71 - 1.84 (4H, m), 1.96 - 2.04 (2H, m), 2.42 - 2.53 (3H, m), 2.57 - 2.66 (2H, m), 2.80 - 2.87 (2H, m), 3.89 (3H, s), 4.35 - 4.44 (3H, m), 6.88 (1H, dd), 6.94 - 6.99 (1H, m), 7.05 - 7.10 (2H, m), 7.37 (1H, d), 7.40 - 7.44 (1H, m), 7.87 (1H, dd)	215-218
2I	4-bromo-N-[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-y]carbonylbenzenesulfonamide	590/592/594		220-223

2J	3,5-dichloro-N-[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonylbenzenesulfonamide	580/582/584	
2K	Methyl 2-[[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]amino]sulfonyl]benzoate	570/572	
2L	2-bromo-N-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]benzenesulfonamide	590/592/594	

2M	5-chloro-N-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperdin]-1'-yl]carbonyl]-2-thiophenesulfonamide	552/554/556	
2N	4,5-dichloro-N-[4-(3,4-dichlorophenoxy)[1,4'-bipiperdin]-1'-yl]carbonyl]-2-thiophenesulfonamide	586/588/590	
2O	4-chloro-N-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperdin]-1'-yl]carbonyl]-2,5-dimethylbenzenesulfonamide	574/576/578	

2P	2,5-dichloro-N-[4-(3,4-dichlorophenoxy)[1,4'-bipiperdin]-1'-yl]carbonyl]-3-thiophenesulfonamide	586/588/590	
2Q	N-[4-(3,4-dichlorophenoxy)[1,4'-bipiperdin]-1'-yl]carbonyl]-2-(trifluoromethoxy)-benzenesulfonamide	596/598	
2R	4-bromo-N-[4-(3,4-dichlorophenoxy)[1,4'-bipiperdin]-1'-yl]carbonyl]-2-thiophenesulfonamide	596/598/600	

2S	N-[4-(3,4-dichlorophenoxy)[1,4'-bipiperdin]-1'-y]carbonyl]-4-(trifluoromethoxy)-benzenesulfonamide	596/598	
2T	5-chloro-N-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperdin]-1'-y]carbonyl]-2,4-difluoro-benzenesulfonamide	582/584/586	
2U	4-chloro-N-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperdin]-1'-y]carbonyl]-2,5-difluoro-benzenesulfonamide	582/584/586	

2V	3-chloro-N-[4-(3,4-dichlorophenoxy)[1,4'-bipiperdin]-1'-yl]carbonyl]-5-fluoro-2-methylbenzenesulfonamide	578/580/582	
2X	N-[4-(3,4-dichlorophenoxy)[1,4'-bipiperdin]-1'-yl]carbonyl]-2,6-dimethylbenzenesulfonamide	540/542	(CD ₃ OD plus 1 drop NaOD) 1.53 (2H, dd), 1.98 - 2.24 (7H, m), 2.63 - 2.74 (2H, m), 2.72 (6H, s), 3.20 - 3.39 (4H, m), 4.43 (2H, d), 4.63 - 4.69 (1H, m), 6.96 (1H, dd), 7.05 (2H, d), 7.14 (1H, dd), 7.21 (1H, d), 7.42 (1H, d)
2Y	N-[4-(3,4-dichlorophenoxy)[1,4'-bipiperdin]-1'-yl]carbonyl]-2-(dimethylamino)-benzenesulfonamide	555/557	(CD ₃ OD plus 1 drop NaOD) 1.27 - 1.42 (2H, m), 1.70 - 1.86 (4H, m), 1.96 - 2.05 (2H, m), 2.41 - 2.54 (3H, m), 2.57 - 2.67 (2H, m), 2.73 (6H, s), 2.80 - 2.88 (2H, m), 4.35 - 4.47 (3H, m), 6.88 (1H, dd), 7.08 - 7.14 (2H, m), 7.30 - 7.43 (3H, m), 7.98 (1H, dd)

2Z	N-[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl-4-(ethylamino)-benzenesulfonamide	555/557	(DMSO) 1.15 (3H, t), 1.20 - 1.28 (2H, m), 1.53 - 1.63 (2H, m), 1.65 - 1.72 (2H, m), 1.88 - 1.96 (2H, m), 2.37 - 2.47 (3H, m), 2.57 - 2.68 (2H, m), 2.70 - 2.79 (2H, m), 3.08 (2H, dt), 3.94 - 4.01 (2H, m), 4.39 - 4.47 (1H, m), 6.38 - 6.43 (1H, m), 6.53 - 6.58 (2H, m), 6.97 (1H, m), 7.25 (1H, d), 7.48 - 7.51 (1H, m), 7.53 - 7.57 (2H, m)	
5B	N-Benzoyl-4-(4-chloro-2-methylphenoxy)-[1,4'-bipiperidine]-1'-sulfonamide	492/494	(CD ₃ OD) 1.57 - 1.73 (m, 2H), 1.75 - 1.88 (m, 2H), 1.90 - 2.07 (m, 4H), 2.19 (s, 3H), 2.37 - 2.49 (m, 1H), 2.50 - 2.61 (m, 2H), 2.73 - 2.91 (m, 4H), 3.80 - 3.90 (m, 2H), 4.36 - 4.45 (m, 1H), 6.87 - 6.91 (m, 1H), 7.07 - 7.13 (m, 2H), 7.32 - 7.46 (m, 3H), 8.04 (d, 2H); (plus 1 drop of 30% NaOD in D ₂ O)	237-238
5C	N-Benzoyl-4-[(3,4-dichlorophenyl)methyl]-[1,4'-bipiperidine]-1'-sulfonamide	510/512	(CD ₃ OD) 8.00 (2H, dt), 7.43 - 7.37 (2H, m), 7.36 - 7.29 (3H, m), 7.09 (1H, dd), 3.81 (2H, d), 2.94 (2H, d), 2.74 (2H, t), 2.53 (2H, d), 2.35 (1H, t), 2.18 (2H, t), 1.89 (3H, s), 1.67 - 1.48 (5H, m), 1.33 - 1.21 (2H, m)	193-196

5D	N-benzoyl-4-(3,4-dichloro-2-methylphenoxy)-[1,4'-bipiperidine]-1'-sulfonamide	526/528	(CD ₃ OD plus 1 drop NaOD) 1.58 - 1.70 (2H, m), 1.76 - 1.86 (2H, m), 1.90 - 1.96 (2H, m), 1.97 - 2.05 (2H, m), 2.31 (3H, s), 2.38 - 2.47 (1H, m), 2.51 - 2.58 (2H, m), 2.74 - 2.88 (4H, m), 3.81 - 3.87 (2H, m), 4.40 - 4.47 (1H, m), 6.91 (1H, d), 7.27 (1H, d), 7.31 - 7.36 (2H, m), 7.38 - 7.43 (1H, m), 8.00 - 8.03 (2H, m)	198-199
5E	N-benzoyl-4-(2,4-dichlorophenoxy)-[1,4'-bipiperidine]-1'-sulfonamide	512/514	(CD ₃ OD plus 1 drop NaOD) 1.58 - 1.70 (2H, m), 1.79 - 1.88 (2H, m), 1.90 - 2.04 (4H, m), 2.38 - 2.47 (1H, m), 2.51 - 2.58 (2H, m), 2.74 - 2.82 (2H, m), 2.84 - 2.92 (2H, m), 3.81 - 3.87 (2H, m), 4.45 - 4.52 (1H, d), 7.08 (1H, d), 7.23 (1H, dd), 7.31 - 7.36 (2H, m), 7.39 - 7.43 (2H, m), 8.00 - 8.03 (2H, m)	233-235
6B	<i>trans</i> N-[4-[4-(3,4-dichlorophenoxy)-1-piperidinylcyclohexyl]carbonyl]-2-methylbenzenesulfonamide	525/527	(CD ₃ OD) 1.33 (4H, d), 1.66 - 1.79 (2H, m), 1.83 - 2.12 (7H, m), 2.25 - 2.37 (1H, m), 2.50 (2H, s), 2.64 (3H, s), 2.78 - 2.89 (2H, m), 4.32 - 4.40 (1H, m), 6.87 (1H, dd), 7.08 (1H, d), 7.22 (2H, d), 7.30 - 7.34 (1H, m), 7.36 (1H, d), 7.98 (1H, d)	

6C	<i>trans N</i> -[4-[4-(3,4-dichlorophenoxy)-1-piperidinylcyclohexyl]carbonyl]-2-methoxybenzenesulfonamide	541/543	(CD ₃ OD) 1.27 - 1.45 (4H, m), 1.70 - 1.81 (2H, m), 1.85 - 2.19 (7H, m), 2.24 - 2.39 (1H, m), 2.45 - 2.58 (2H, m), 2.80 - 2.91 (2H, m), 3.89 (3H, s), 4.33 - 4.44 (1H, m), 6.85 - 7.13 (4H, m), 7.35 - 7.50 (2H, m), 7.87 - 7.92 (1H, m)
6D	<i>trans N</i> -[4-[4-(3,4-dichlorophenoxy)-1-piperidinylcyclohexyl]carbonyl]-2,6-dimethylbenzenesulfonamide	539/541	(CD ₃ OD) 1.34 (4H, d), 1.64 - 1.80 (2H, m), 1.85 - 2.14 (7H, m), 2.25 - 2.37 (1H, m), 2.45 - 2.57 (2H, m), 2.73 (6H, s), 2.80 - 2.90 (2H, m), 4.32 - 4.41 (1H, m), 6.85 - 6.92 (1H, m), 7.00 - 7.21 (4H, m), 7.38 (1H, d)
6E	<i>trans N</i> -[4-[4-(3,4-dichlorophenoxy)-1-piperidinylcyclohexyl]carbonyl]-4-methylbenzenesulfonamide	525/527/529	(CD ₃ OD plus 1 drop NaOD) 1.26 - 1.41 (4H, m), 1.72 - 1.82 (2H, m), 1.88 - 2.13 (7H, m), 2.28 - 2.37 (1H, m), 2.40 (3H, s), 2.53 (2H, s), 2.86 (2H, s), 4.40 (1H, s), 6.90 (1H, dd), 7.11 (1H, d), 7.27 (2H, d), 7.39 (1H, d), 7.79 (2H, d);

6F	<i>trans N</i> -[4-[4-(3,4-dichlorophenoxy)-1-piperidiny]cyclohexyl carbonyl]-benzenesulfonamide	511/513/515	(CD ₃ OD plus 1 drop NaOD) 6.78 (1H, d), 6.99 (1H, d), 7.27 (1H, d), 7.30 - 7.38 (3H, m), 7.76 - 7.83 (2H, m) (of aromatic region only)
6G	<i>trans N</i> -[4-[4-(3,4-dichlorophenoxy)-1-piperidiny]cyclohexyl carbonyl]-4-(dimethylamino)-benzenesulfonamide	554/556/558	(CD ₃ OD plus 1 drop NaOD) 1.27 - 1.46 (4H, m), 1.71 - 1.85 (2H, m), 1.88 - 2.12 (7H, m), 2.31 - 2.40 (1H, m), 2.53 (2H, t), 2.86 (2H, d), 3.03 (6H, s), 4.36 - 4.45 (1H, m), 6.73 (2H, d), 6.91 (1H, dd), 7.11 (1H, d), 7.40 (1H, d), 7.74 (2H, d)
8B	N-(3-cyanobenzoyl)-4-(3,4-dichlorophenoxy)-[1,4'-bipiperidine]-1'-sulfonamide	537/539	(DMSO) 1.55 - 1.80 (4H, m), 1.92 - 2.18 (6H, m), 2.63 - 2.75 (2H, m), 3.00 - 3.26 (4H, m), 3.59 - 3.77 (2H, m), 6.96 - 7.11 (1H, m), 7.29 - 7.41 (1H, m), 7.44 - 7.63 (2H, m), 7.85 (1H, d), 8.21 (2H, dt)

8C	4-(3,4-dichlorophenoxy)-N-(4-fluorobenzoyl)-[1,4'-bipiperidine]-1'-sulfonamide	530/532	(DMSO) 1.55 - 1.80 (3H, m), 1.92 - 2.18 (6H, m), 2.63 - 2.75 (2H, m), 3.00 - 3.26 (4H, m), 3.59 - 3.77 (2H, m) 3.59 - 3.78 (1H, m), 6.89 - 7.24 (3H, m), 7.33 (1H, s), 7.53 (1H, d), 7.96 (2H, dd)	141-143
8D	4-(3,4-dichlorophenoxy)-N-[3-(methylsulfonyl)benzoyl]-[1,4'-bipiperidine]-1'-sulfonamide	590/592	(DMSO) 1.46 - 2.20 (10H, m), 2.62 - 2.80 (6H, m), 3.24 - 3H, s), 3.66 - 3.76 (2H, m), 7.04 (1H, s), 7.35 (1H, s), 7.54 (1H, d), 7.62 (1H, t), 7.95 (1H, d), 8.23 (1H, dt), 8.42 (1H, t)	244-246
8E	4-(4-chloro-2-methylphenoxy)-N-[3-(methylsulfonyl)benzoyl]-[1,4'-bipiperidine]-1'-sulfonamide	570/572	(DMSO) 1.51 - 1.79 (4H, m), 1.91 - 2.24 (8H, m), 2.64 - 2.75 (3H, m), 3.20 (3H, s), 3.66 - 3.75 (2H, m), 4.43 - 4.81 (1H, m), 6.98 - 7.05 (1H, m), 7.19 (1H, dd), 7.24 (1H, d), 7.62 (1H, t), 7.94 (1H, d), 8.23 (1H, dt), 8.42 (1H, t)	235-236

8F	N-(2-chlorobenzoyl)-4-(3,4-dichlorophenoxy)-[1,4'-bipiperidine]-1'-sulfonamide	546/548/550	(DMSO) 1.44 - 1.73 (4H, m), 1.86 - 2.17 (6H, m), 2.63 - 2.77 (2H, m), 3.03 - 3.16 (4H, m), 3.64 - 3.72 (2H, m), 7.03 (1H, d), 7.32 - 7.42 (3H, m), 7.54 (1H, d), 7.92 (2H, dt)	187-188
8G	N-(4-chlorobenzoyl)-4-(3,4-dichlorophenoxy)-[1,4'-bipiperidine]-1'-sulfonamide	546/548/550	(DMSO) 0.92 - 2.22 (11H, m), 2.57 - 2.78 (6H, m), 3.63 - 3.77 (1H, m), 7.03 (1H, d), 7.31 - 7.41 (3H, m), 7.54 (1H, d), 7.92 (2H, dd)	156-157
8H	N-(4-chlorobenzoyl)-4-(4-chloro-2-methylphenoxy)-[1,4'-bipiperidine]-1'-sulfonamide	526/528	(DMSO) 1.02 - 1.61 (4H, m), 1.63 - 2.03 (3H, m), 2.13 - 2.19 (2H, m), 2.52 (3H, s), 2.56 - 2.69 (3H, m), 2.97 - 3.14 (4H, m), 3.52 - 3.78 (2H, m), 7.00 (1H, d), 7.16 (1H, dd), 7.22 (1H, d), 7.32 - 7.39 (2H, m), 7.91 (2H, dt)	138-139

9B	4-(3,4-dichlorophenoxy)-N-(2-methoxybenzoyl)-[1,4'-bipiperidine]-1'-sulfonamide	542/544	(DMSO) 0.95 - 1.31 (3H, m), 1.31 - 1.96 (6H, m), 2.24 (3H, s), 2.57 - 2.75 (7H, m), 3.55 - 3.73 (2H, m), 6.95 - 7.05 (2H, m), 7.13 (1H, d), 7.26 (1H, d), 7.47 (3H, dd)	202-203
9C	4-(3,4-dichlorophenoxy)-N-(4-methoxybenzoyl)-[1,4'-bipiperidine]-1'-sulfonamide	542/544	(DMSO) 1.40 - 2.19 (6H, m), 2.70 - 2.89 (5H, m), 2.95 - 3.13 (2H, m), 3.68 - 3.79 (4H, m), 3.87 (3H, s), 4.43 - 4.66 (1H, m), 6.95 (2H, d), 7.01 (1H, dd), 7.30 (1H, d), 7.52 (1H, d), 7.90 (2H, dd)	142-143
10B	N-[(4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-2-methylbenzenesulfonamide sodium salt	526/528	(DMSO) 1.16 (2H, qd), 1.50 - 1.61 (4H, m), 1.87 - 1.94 (2H, m), 2.28 - 2.46 (5H, m), 2.69 - 2.75 (2H, m), 4.18 - 4.27 (2H, m), 4.39 (1H, septet), 6.97 (1H, dd), 7.11 (2H, t), 7.20 (1H, td), 7.25 (1H, d), 7.48 (1H, d), 7.74 (1H, d)	

10C	N-[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl- benzenesulfonamide sodium salt	512/514	(DMSO) 1.16 (2H, qd), 1.49 - 1.62 (4H, m), 1.87 - 1.94 (2H, m), 2.27 - 2.46 (5H, m), 2.69 - 2.75 (2H, m), 4.17 - 4.26 (2H, m), 4.39 (1H, septet), 6.97 (1H, dd), 7.25 (1H, d), 7.29 - 7.33 (3H, m), 7.48 (1H, d), 7.69 - 7.72 (2H, m)	
10D	N-[4-(4-chloro-2-methyl[phenoxyl][1,4'-bipiperidin]-1'-yl]carbonyl)-4-methyl- benzenesulfonamide sodium salt	506/508	(DMSO) 1.10 - 1.21 (2H, m), 1.54 - 1.65 (4H, m), 1.83 - 1.91 (2H, m), 2.28 (3H, s), 2.12 (3H, d), 2.30 - 2.46 (5H, m), 2.65 - 2.72 (2H, m), 4.20 (2H, d), 4.32 - 4.39 (1H, m), 6.97 (1H, d), 7.10 (2H, d), 7.13 (1H, dd), 7.19 (1H, dd), 7.58 (2H, d)	
16B	4-(3,4-dichlorophenoxy)-N-[4-(1,1-dimethylethyl)phenyl]sulfonyl]-[1,4'-bipiperidine]-1'-sulfonamide	604/606/608		274-276 recrystallised from DMSO-methanol

The preparations of certain intermediates are now presented.

Method A

[1,4']Bipiperidinyl-4-ol

5 4-Oxo-piperidine-1-carboxylic acid *tert*-butyl ester (20g) and 4-hydroxypiperidine (6.7g) were stirred together in dichloroethane (200ml) with acetic acid (4ml) at RT for 30 minutes. Sodium triacetoxoborohydride (23g) was then added and the mixture stirred at RT overnight. The mixture was evaporated to dryness and the residue taken into water, extracted with diethyl ether (3x 200ml), the aqueous was basified to pH 9-10 and extracted with dichloromethane (3x 200ml). The dichloromethane extracts were combined, dried 10 (MgSO₄) and evaporated to leave an oil (19g). The oil was dissolved in methanol (300ml) and treated with concentrated hydrochloric acid (5ml). The mixture was stirred overnight and then evaporated to dryness to leave the title compound as the hydrochloride salt (15g).

15 ¹H NMR (400MHz, DMSO-D6) δ 1.6-2.4 (m, 9H), 2.8-3.5 (m, 8H), 3.62 (m, 1H), 3.95 (s, 1H), 9.29 and 9.059 (bs, 2H), 10.9 and 11.09 (bs, 1H).

Method B

4-(3,4-Dichlorophenoxy)piperidine

Step a: *tert*-Butyl 4-(3,4-dichlorophenoxy)-1-piperidinecarboxylate

20 Diethyl azodicarboxylate (41.0ml) was added to a solution of triphenylphosphine (62.9g) in tetrahydrofuran (800ml) at 0°C. After 15 minutes 3,4-dichlorophenol (39.1g) was added, after a further 15 minutes *tert*-butyl 4-hydroxy-1-piperidinecarboxylate (48.3g) in tetrahydrofuran (400ml) was added dropwise over 30 min. The solution was stirred at room temperature for 16 hours and concentrated to a small volume. Purification by chromatography (ethyl acetate : *iso*-hexane 95:5) gave the sub-title compound as an oil (61.3g).

25 MS: APCI(+ve): 246/248 (M-BOC+2H)

Step b: 4-(3,4-Dichlorophenoxy)piperidine

30 The product from Step a was dissolved in dichloromethane (600ml) and trifluoroacetic acid (300ml) was added. After 24 hours at room temperature the solution was evaporated and the resultant gum triturated under ether to give the sub-title product as a solid (36.6g). The free base was liberated by addition of aqueous NaOH (2M) and extraction with ethyl acetate followed by evaporation of solvent to give the title compound as a gum (25g).

¹H NMR: δ(CDCl₃) 1.77 (1H, br s), 2.05-2.26 (4H, m), 3.20-3.49 (4H, m), 4.61 (1H, s), 6.69-7.52 (3H, m).

Method C

4-(3,4-Dichlorophenoxy)-[1,4']bipiperidine

5 Step a: 4-(3,4-Dichlorophenoxy)-[1,4']bipiperidinyl-1'-carboxylic acid *tert*-butyl ester
 4-(3,4-Dichlorophenoxy)piperidine (1.5g) was dissolved in 1,2-dichloroethane (21ml). 1-Boc-4-piperidone was added (1.21g) followed by NaBH(OAc)₃ (1.81g) and acetic acid (0.37g). After 18 hours at room temperature aqueous NaOH (1M) solution and diethyl ether were added. The product was extracted with diethyl ether, the combined
 10 organic extracts dried with MgSO₄ and concentrated. Purification by chromatography (dichloromethane : methanol 92:8) gave the sub-title product (1.97g; MS: APCI(+ve): 429/431 (M+H)).

Step b: 4-(3,4-Dichloro-phenoxy)-[1,4']bipiperidine

The product of Step a was dissolved in dichloromethane (30ml) and trifluoroacetic acid (15ml) was added. After 4 hours at room temperature the solution was evaporated and the resultant gum triturated under ether to give the trifluoroacetate salt of the sub-titled product as a solid (1.15g). The free base was liberated by addition of aqueous NaOH (2M) and extraction with ethyl acetate followed by evaporation of solvent to give the sub-title compound as a solid (0.68g).

20 ¹H NMR: δ(CDCl₃) 1.38-1.51 (2H, m), 1.74-2.02 (6H, m), 2.38-2.50 (3H, m), 2.56-2.61 (2H, m), 2.79-2.86 (2H, m), 3.14-3.18 (2H ,m), 4.22-4.28 (1H, m), 6.73-7.32 (3H, m).

The following intermediates were prepared in a similar manner to Method C:

	MS: (M+H)
4-(4-chloro-2-methylphenoxy)-1,4'-bipiperidine	309/311
4-(2-chloro-4-fluorophenoxy)-1,4'-bipiperidine	313/315
4-(3,4-diflorophenoxy)-1,4'-bipiperidine	297
4-(2,4-dichlorophenoxy)-1,4'-bipiperidine	329/331
4-(2,4-dichloro-3-methylphenoxy)-1,4'-bipiperidine	343/345
4-(3,4-dichloro-2-methylphenoxy)-1,4'-bipiperidine	343/345
¹ 4-[(3,4-Dichlorophenyl)methyl]-1,4'-bipiperidine	327/329
² 2-([1,4'-bipiperidin]-4-yloxy)-5-chloro-pyridine	³

1 for starting material see DE19837386

2 for starting material see WO 00/12478

3 ^1H NMR (399.978MHz, CDCl_3): δ 1.44 (2H, qd), 1.74 - 1.86 (5H, m), 2.01 - 2.07 (2H, m), 2.38 - 2.42 (1H, m), 2.44 - 2.50 (2H, m), 2.60 (2H, td), 2.82 - 2.87 (2H, m), 3.15 (2H, d), 4.98 (1H, septet), 6.66 (1H, d), 7.50 (1H, dd), 8.06 (1H, d).

5

Method D

4-(3-Chloro-4-fluoro-phenoxy)-piperidine

DEAD (0.43ml) was added to a solution of triphenylphosphine (0.72g), 3-chloro-4-fluorophenol (0.403g) and 4-hydroxy-piperidine-1-carboxylic acid tert-butyl ester (0.5g) in 10 THF at RT. The resulting mixture was stirred overnight, HCl in dioxan (2ml of 4M) was added and the mixture stirred at RT overnight. The mixture was then evaporated to dryness and triethylamine (5ml) was added. The mixture was evaporated and the residue was dissolved in methanol (10ml), placed onto a SCX cartridge (Varian, 10g, SCX cartridge available from International Sorbent Technology Isolute® Flash SCX-2) and 15 eluted: first with methanol then with 10% NH_3 in methanol. The basic fractions were combined and evaporated to give the product as an oil (0.6g).

^1H NMR (299.946 MHz, DMSO-D6) δ 1.34 - 1.46 (2H, m), 1.83 - 1.91 (2H, m), 2.53 - 2.59 (2H, m), 2.87 - 2.96 (2H, m), 3.22 - 3.39 (1H, m), 4.39 (1H, septet), 6.92 - 6.98 (1H, m), 7.17 - 7.20 (1H, m), 7.30 (1H, t).

20 The following intermediates were prepared in similar manner to Method D:

	MS: (M+H)
4-(4-chloro-2-methyl-phenoxy)-piperidine	226/228
4-(4-chloro-3-fluoro-phenoxy)-piperidine	230/232
4-(4-chloro-2-methoxy-phenoxy)-piperidine	242/244
4-(4-fluoro-2-methoxy-phenoxy)-piperidine	226
4-(4-methoxy-phenoxy)-piperidine	208
4-p-tolyloxy-piperidine	192
4-(4-chloro-3-methyl-phenoxy)-piperidine	226/228
4-(4-chloro-phenoxy)-piperidine	212/214
4-(4-fluoro-phenoxy)-piperidine	196
4-(2,4-dichloro-phenoxy)-piperidine	246/248
4-(2-chloro-4-fluoro-phenoxy)-piperidine	230/232

4-(2,4-difluoro-phenoxy)-piperidine	214
4-(4-chloro-2-fluoro-phenoxy)-piperidine	230/232
4-(4-fluoro-2-methyl-phenoxy)-piperidine	210
4-(4-chloro-2,6-dimethyl-phenoxy)-piperidine	240/242
4-(2,3-dichloro-phenoxy)-piperidine	246/248
4-(2,5-dichloro-phenoxy)-piperidine	246/248
4-(2-chloro-4-methyl-phenoxy)-piperidine	226/228
4-(2-chloro-5-methyl-phenoxy)-piperidine	226/228
1-[3-methyl-4-(piperidin-4-yloxy)-phenyl]-ethanone	234
4-(2-chloro-6-methyl-phenoxy)-piperidine	226/228
4-(4-chloro-2-ethyl-phenoxy)-piperidine	240/242
7-(piperidin-4-yloxy)-quinoline	229
4-(2-tert-butyl-phenoxy)-piperidine	234
4-(indan-5-yloxy)-piperidine	218
4-(4-chloro-2-cyclohexyl-phenoxy)-piperidine	294/296
5-chloro-2-(piperidin-4-yloxy)-benzamide	255/257
4-(4-chloro-2-isoxazol-5-yl-phenoxy)-piperidine	279/281
4-(5-chloro-2-methyl-phenoxy)-piperidine	226/228
4-phenoxy-piperidine	178
4-(2,4-dichloro-6-methyl-phenoxy)-piperidine	260/262
4-(3-chloro-4-methyl-phenoxy)-piperidine	226/228
5-chloro-2-(piperidin-4-yloxy)-benzonitrile	237/239
4-(2,4-dichloro-3-methyl-phenoxy)-piperidine	260/262
4-(2-ethyl-4-fluoro-phenoxy)-piperidine	224
4-(4-methanesulfonyl-phenoxy)-piperidine	297
4-(3,4-dichloro-2-methylphenoxy)-piperidine	260/262

Method E4-(3,4-Dichlorophenoxy)-4'-methyl-1,4'-bipiperidine dihydrochloride

a) 1,1-Dimethylethyl 4'-cyano-4-(3,4-dichlorophenoxy)-[1,4'-bipiperidine]-1'carboxylate

5 4-(3,4-Dichlorophenoxy)piperidine (Method B step b; 500mg) was dissolved in dichloroethane (2ml) with 1-Boc-4-piperidone (446mg). Titanium teraisopropoxide

(0.85ml) was added and the mixture was stirred overnight. The solvent was evaporated and toluene (5ml) was added followed by diethylaluminium cyanide (3ml of 1M solution in toluene). The mixture was stirred for 3h, then ethyl acetate was added (5ml) followed by water (0.5ml) and the mixture was stirred for a further 2h. The mixture was filtered through a GF filter paper, and evaporated to give the subtitle compound (912mg; MS [M+H]⁺ (APCI+) 454/456).

¹H NMR (399.98 MHz, CD₃OD) δ 1.36 (s, 9H), 1.57 - 1.77 (m, 4H), 1.90 - 1.99 (m, 2H), 2.04 - 2.12 (m, 2H), 2.44 - 2.52 (m, 2H), 2.77 - 2.87 (m, 2H), 3.02 - 3.13 (m, 2H), 3.82 (dt, 2H), 4.31 - 4.40 (m, 1H), 6.81 (dd, 1H), 7.02 (d, 1H), 7.29 (d, 1H).

10

b) 1,1-Dimethylethyl 4-(3,4-dichlorophenoxy)- 4'-methyl-[1,4'-bipiperidine]-1'-carboxylate
1,1-Dimethylethyl 4'-cyano-4-(3,4-dichlorophenoxy)-[1,4'-bipiperidine]-1'-carboxylate (100mg) was dissolved in THF (6ml). Methyl magnesium bromide (3M in ether, 220μl) was added and the mixture was stirred at RT for 2h. Further methyl magnesium bromide (220μl) was added and the solution was stirred for a further 60h. Potassium carbonate solution (saturated aqueous) was added and the mixture was extracted with DCM. The organic phase was dried, filtered and evaporated to give the subtitle compound (100mg; MS [M+H]⁺ (APCI+) 443/445).

¹H NMR (299.945 MHz, CD₃OD) δ 1.01 (s, 3H), 1.47 (s, 9H), 1.69 - 1.84 (m, 4H), 1.97 - 2.08 (m, 2H), 2.42 - 2.52 (m, 2H), 2.81 - 2.92 (m, 2H), 3.36 - 3.42 (m, 2H), 3.45 - 3.57 (m, 2H), 3.62 - 3.89 (m, 2H), 4.32 - 4.41 (m, 1H), 6.89 (dd, 1H), 7.10 (d, 1H), 7.38 (d, 1H).

c) 4-(3,4-dichlorophenoxy)- 4'-methyl-1,4'-bipiperidine dihydrochloride
1,1-Dimethylethyl 4-(3,4-dichlorophenoxy)- 4'-methyl-[1,4'-bipiperidine]-1'-carboxylate (100mg) was dissolved in ethanol (5ml). Hydrogen chloride (2ml of 4M in dioxan) was added and the solution was stirred overnight. Further hydrogen chloride solution (2ml) was added and the mixture was stirred for a further 2h. The solvents were evaporated to give the title compound (95mg; MS [M+H]⁺ (APCI+) 343/345).

Method F

30 trans Sodium 4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]-cyclohexanecarboxylate

a) Ethyl 4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]-cyclohexanecarboxylate
4-(3,4-Dichlorophenoxy)piperidine (Method B, 1.44g), ethyl 4-oxocyclohexanecarboxylate (1.0g) and acetic acid (0.34ml) were combined in THF 10ml

and the solution was cooled in ice. Sodium triacetoxy borohydride (1.45g) was added and the mixture was stirred overnight and allowed to come to ambient temperature. The reaction mixture was poured onto a stirred saturated aq solution of sodium bicarbonate. The mixture was extracted with ethyl acetate thrice, the organic phases were washed with brine, dried, filtered and evaporated. The residue was purified on an SCX cartridge (International Sorbent Technology Isolute® Flash SCX-2), washed with methanol and then product eluted with 0.7M ammonia in methanol. Further purification by chromatography (silica, 90:9:1 DCM : methanol : triethylamine) gave the subtitle compound (1.59g; MS $[M+H]^+$ (APCI+) 400/402) as a mixture of cis/trans isomers.

10 ^1H NMR (399.98 MHz, CD₃OD) δ 1.23 (t), 1.25 (t), 1.28 - 1.59 (m), 1.70 - 1.81 (m), 1.96 - 2.07 (m), 2.17 - 2.27 (m), 2.32 - 2.40 (m), 2.45 - 2.56 (m), 2.58 - 2.61 (m), 2.80 - 2.89 (m), 3.30 (quintet), 4.10 (q), 4.14 (q), 4.34 - 4.40 (m), 6.88 (dd), 6.88 (dd), 7.09 (d), 7.09 (d), 7.37 (d), 7.37 (d).

15 b) *trans* Sodium 4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]-cyclohexanecarboxylate
Ethyl 4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]-cyclohexanecarboxylate (0.97g) was added to a solution of sodium ethoxide in ethanol (prepared from sodium (1.28g) and ethanol (100ml)). The solution was heated to reflux overnight. Acetic acid was added and the solvent was evaporated. Ethyl acetate, water and sodium hydroxide were added to the residue and an insoluble white solid formed which was collected by filtration and dried in vacuo to give the sub-titled compound (469mg; MS $[M-\text{Na}]^-$ (APCI-) 370/372) containing sodium acetate.

20 ^1H NMR (399.98MHz, CD₃OD) δ 1.27 - 1.38 (m, 2H), 1.46 (q, 2H), 1.72 - 1.81 (m, 2H), 1.95 - 2.09 (m, 7H), 2.40 (t, 1H), 2.55 (td, 2H), 2.84 - 2.91 (m, 2H), 4.39 (septet, 1H), 6.89 (dd, 1H), 7.10 (d, 1H), 7.37 (d, 1H).

Method G

4-(3,4-Dichlorophenoxy)-[1,4'-bipiperidine]-1'-sulfonamide

25 4-(3,4-Dichlorophenoxy)-1,4'-bipiperidine (5g, 0.0152 mol) and sulfamide (1.45g, 0.0152 mol) were stirred together in dioxan (150ml) at reflux for 24 hours. The resulting mixture was cooled to ambient temperature, evaporated to dryness and the residue was triturated with ether to give the title compound as a tan solid (5g; MS APCI 409/411 (M+H)).

¹H NMR (399.98 MHz, DMSO) δ 1.38 - 2.03 (m, 6H), 2.25 - 2.45 (m, 6H), 2.66 - 2.84 (m, 3H), 3.41 - 3.53 (m, 2H), 4.35 - 4.47 (m, 1H), 6.31 - 6.45 (m, 2H), 6.91 - 7.03 (m, 1H), 7.18 - 7.31 (m, 1H), 7.43 - 7.55 (m, 1H).

Method H

5 4-(3,4-Dichlorophenoxy)-[1,4'-bipiperidine]-1'-carboxamide.

4-(3,4-Dichlorophenoxy)-1,4'-bipiperidine (2.0g) was dissolved in glacial acetic acid (0.608ml), the solution was diluted with water (6ml) and added with stirring to a solution of sodium cyanate (0.395g) in warm water (3ml). The reaction was allowed to stand for 30 mins. 2M Sodium hydroxide solution was added until the solution was 10 alkaline. The resulting precipitate was collected and washed with water followed by dichloromethane and then dried to leave the sub-title compound (1.3g; ES+ 372/374).

15 ¹H NMR (399.98 MHz, DMSO) δ 1.20 - 1.31 (m, 2H), 1.51 - 1.61 (m, 2H), 1.62 - 1.69 (m, 2H), 1.88 - 1.95 (m, 2H), 2.32 - 2.44 (m, 3H), 2.55 - 2.64 (m, 2H), 2.70 - 2.77 (m, 2H), 3.92 - 3.99 (m, 2H), 4.37 - 4.44 (m, 1H), 5.86 (s, 2H), 6.95 - 6.99 (m, 1H), 7.24 - 7.25 (m, 1H), 7.49 (d, 1H).

Method I

2,4-Dichloro-3-fluorophenol

a) *N,N*-Diethyl-4-chloro-3-fluorophenyl carbamate

A solution of 4-chloro-3-fluorophenol (26.9g) and diethylcarbamoyl chloride (25g) 20 in pyridine (100ml) was heated to 100°C for 12 h and then allowed to cool. Water (100ml) was added and the product was extracted with diethylether/pentane (1:1) (50mlx2). The combined organic extracts were washed with HCl (2M, 70ml), NaOH (2M, 75ml) and dried ($MgSO_4$), filtered and evaporated to give the subtitle compound as an oil (37.7g)

15 ¹H NMR δ (CDCl₃) 1.18 - 1.26 (6H, m), 3.35 - 3.44 (4H, m), 6.90 (1H, ddd), 6.99 - 7.02 (1H, m), 7.35 (1H, t)

b) *N,N*-Diethyl-2,4-dichloro-3-fluorophenyl carbamate

To a solution of *N,N*-diethyl-4-chloro-3-fluorophenyl carbamate (15g) in THF (100ml) and TMEDA (9.7ml) at -90°C was added *sec*BuLi (1.3M, 49.5ml) whilst maintaining the temperature between -80°C and -90°C. The mixture was stirred at -80°C 30 for 2h. 1,1,1,2,2,2-Hexachloroethane (17.39g) as a solution in THF (50ml) was added. During this period the reaction was allowed to warm to 0°C. Water (50ml) was added and the product was extracted with pentane. The combined organic extracts were dried ($MgSO_4$) and filtered. Evaporation of solvent and purification by HPLC (Waters Xterra®)

column)(gradient (25% MeCN/NH₃(aq) (0.1%) to 95% MeCN/NH₃(aq) (0.1%)) gave the subtitle compound as an oil (9.3g).

¹H NMR δ (CDCl₃) 1.19 - 1.32 (6H, m), 3.36 - 3.51 (4H, m), 7.03 (1H, dq), 7.26 - 7.33 (1H, m).

5 2,4-Dichloro-3-fluorophenol

N,N-Diethyl-2,4-dichloro-3-fluorophenyl carbamate (8.14g) was dissolved in THF (17ml). A solution of lithium aluminium hydride (33ml of 1M in THF) was added dropwise and the resulting solution was stirred overnight. Ethanol was added followed by hydrochloric acid (2M, 17ml). The resulting suspension was filtered and the solid was washed with ether. The phases were separated, the aqueous phase was extracted thrice with ether and the combined organic phases were dried (MgSO₄), filtered and evaporated to give the title compound (3.4g).

¹H NMR δ (CD₃OD) 6.65 (1H, dd), 7.11 (1H, t)

Method J

15 2,6-Dimethyl-benzenesulfonamide

To a solution of 2,6-dimethyl-benzenethiol (2ml) in water (20ml), chlorine gas was introduced over 15 minutes resulting in precipitation of an orange solid. The reaction was left to stir in a stoppered flask for a further 60 minutes. An excess of ammonia solution (0.88 sg) was added and the mixture was left to stir for 12h. The reaction was evaporated to remove ammonia and then filtered. The solid was washed with water followed by isohexane to give the title compound.

MS [M-H]⁻ (ES-) 184

¹H NMR δ (DMSO) 2.59 (6H, s), 7.18 (2H, d), 7.27 (2H, s), 7.30 (1H, t)

Method K

25 trans 4-[4-(3,4-Dichlorophenoxy)-1-piperidinyl]-cyclohexanecarboxylic acid

a) *trans* Ethyl 4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]-cyclohexanecarboxylate

Ethyl 4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]-cyclohexanecarboxylate (method F, step a, 0.97g) was added to a solution of sodium ethoxide prepared from sodium (1.28g) and ethanol (100ml). The resultant solution was heated under reflux for 18h. Acetic acid (0.1ml) was added and the solvent was evaporated. Ethyl acetate, water and sodium hydroxide were added to the residue and separated. The aqueous phase was extracted twice with ethyl acetate-methanol mixtures and the combined organic phases were washed with brine, dried (MgSO₄), filtered and evaporated to give the subtitle compound as an oil.

MS [M+H]⁺ (APCI+) 400/402

¹H NMR of major isomer (ca 3.5:1 ratio) δ (acetone) 1.20 (3H, t), 1.27 - 1.46 (4H, m), 1.57 - 1.71 (3H, m), 1.84 - 1.90 (2H, m), 1.95 - 2.02 (4H, m), 2.15 - 2.23 (1H, m), 2.27 - 2.41 (2H, m), 2.46 (2H, ddd), 4.06 (2H, q), 4.40 (1H, septet), 6.95 (1H, dd), 7.15 (1H, d), 7.43

5 (1H, d)

b) *trans* 4-[4-(3,4-Dichlorophenoxy)-1-piperidinyl]-cyclohexanecarboxylic acid

trans Ethyl 4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]-cyclohexanecarboxylate (0.8g) was dissolved in t-BuOH (180ml) at 38°C. To this was added Candia rugosa lipase powder (3g). This was stirred for 30 minutes then water (20ml) was added over 4 h. The 10 mixture was then stirred for 48h and filtered. The enzyme was washed with 9:1 t-BuOH - water (2 x20ml) and the filtrate was evaporated. Ethyl acetate was added to the residue and then decanted. The resultant solid was dissolved in methanol/DMSO and was purified by HPLC (Waters Xterra® column with at-column dilution of sample) (gradient (5% MeCN/NH3(aq) (0.2%) to 40% MeCN//NH3(aq) (0.2%)) gave the title compound (0.44g) 15 as a white solid.

m.pt. 167-168°C

MS [M+H]⁺ (ES+) 372/374

¹H NMR δ_(DMSO) 1.19 - 1.36 (4H, m), 1.50 - 1.59 (2H, m), 1.78 (2H, d), 1.87 - 1.96 (4H, m), 2.09 (1H, td), 2.24 - 2.32 (1H, m), 2.38 (2H, td), 2.72 (2H, dt), 4.39 (1H, septet), 6.97 20 (1H, dd), 7.24 (1H, d), 7.49 (1H, d)

Method L

1,1-Dimethylethyl [4-(3,4-dichlorophenoxy)-1,4'-bipiperidin-1'-yl]sulfonylcarbamate

tert-Butanol (0.48ml) in dichloromethane (2ml) was added to a solution of chlorosulfonylisocyanate (0.43 ml) in dichloromethane (5ml) stirring at 0°C. The resulting 25 solution was then added to a solution of 4-(3,4-dichlorophenoxy)-1,4'-bipiperidine (1.6g) and triethylamine (0.77ml) in dichloromethane (20ml) at 0°C. After stirring at 0°C for 2h, the reaction mixture was washed with 0.1M hydrochloric acid (30ml), dried (MgSO₄) and evaporated. The residue was triturated with diethylether (20ml) to give the title compound as a white solid. (1.9g)

30 ¹H NMR δ_(DMSO) 1.44 (9H, s), 1.64 - 1.77 (2H, m), 1.94 - 2.08 (2H, m), 2.15 - 2.27 (4H, m), 2.86 (2H, t), 3.03 - 3.18 (2H, m), 3.28 - 3.53 (3H, m), 3.76 (2H, d), 4.59 - 4.81 (1H, m), 6.99 - 7.11 (1H, m), 7.33 - 7.39 (1H, m), 7.52 - 7.58 (1H, m)

EXAMPLE 17Pharmacological Analysis: Calcium flux $[Ca^{2+}]_i$ assayHuman eosinophils

Human eosinophils were isolated from EDTA anticoagulated peripheral blood as previously described (Hansel et al., *J. Immunol. Methods*, 1991, 145, 105-110). The cells were resuspended ($5 \times 10^6 ml^{-1}$) and loaded with $5 \mu M$ FLUO-3/AM + Pluronic F127 $2.2 \mu l/ml$ (Molecular Probes) in low potassium solution (LKS; NaCl 118mM, MgSO₄ 0.8mM, glucose 5.5mM, Na₂CO₃ 8.5mM, KCl 5mM, HEPES 20mM, CaCl₂ 1.8mM, BSA 0.1%, pH 7.4) for one hour at room temperature. After loading, cells were centrifuged at 200g for 5min and resuspended in LKS at $2.5 \times 10^6 ml^{-1}$. The cells were then transferred to 96 well FLIPR plates (Poly-D-Lysine plates from Becton Dickinson pre-incubated with $5 \mu M$ fibronectin for two hours) at $25 \mu l$ /well. The plate was centrifuged at 200g for 5min and the cells were washed twice with LKS (200 μl ; room temperature).

A compound of the Examples was pre-dissolved in DMSO and added to a final concentration of 0.1% (v/v) DMSO. Assays were initiated by the addition of an A₅₀ concentration of eotaxin and the transient increase in fluo-3 fluorescence ($l_{Ex} = 490nm$ and $l_{Em} = 520nm$) monitored using a FLIPR (Fluorometric Imaging Plate Reader, Molecular Devices, Sunnyvale, U.S.A.).

Compounds of the Examples were found to be antagonists if the increase in fluorescence induced by eotaxin (a selective CCR3 agonist) was inhibited in a concentration dependent manner. The concentration of antagonist required to inhibit the fluorescence by 50% can be used to determine the IC₅₀ for the antagonist at the CCR3 receptor.

Human eosinophil chemotaxis

Human eosinophils were isolated from EDTA anticoagulated peripheral blood as previously described (Hansel et al., *J. Immunol. Methods*, 1991, 145, 105-110). The cells were resuspended at $10 \times 10^6 ml^{-1}$ in RPMI containing 200 IU/ml penicillin, 200 $\mu g/ml$ streptomycin sulfate and supplemented with 10% HIFCS, at room temperature.

Eosinophils (700 μl) were pre-incubated for 15 mins at 37° C with 7 μl of either vehicle or compound (100x required final concentration in 10% DMSO). The chemotaxis plate (ChemoTx, 3 μm pore, Neuroprobe) was loaded by adding 28 μl of a concentration of eotaxin 0.1 to 100nM (a selective CCR3 agonist over this concentration range) containing a concentration of a compound according to the Examples or solvent to the lower wells of the


chemotaxis plate. The filter was then placed over the wells and 25 µl of eosinophil suspension were added to the top of the filter. The plate was incubated for 1 hr at 37° C in a humidified incubator with a 95% air/5% CO₂ atmosphere to allow chemotaxis.

The medium, containing cells that had not migrated, was carefully aspirated from above the filter and discarded. The filter was washed once with phosphate buffered saline (PBS) containing 5 mM EDTA to remove any adherent cells. Cells that had migrated through the filter were pelleted by centrifugation (300xg for 5 mins at room temperature) and the filter removed and the supernatant transferred to each well of a 96-well plate (Costar). The pelleted cells were lysed by the addition of 28 µl of PBS containing 0.5% Triton x100 followed by two cycles of freeze/thawing. The cell lysate was then added to the supernatant. The number of eosinophils migrating was quantified according to the method of Strath et al., *J. Immunol. Methods*, 1985, 83, 209 by measuring eosinophil peroxidase activity in the supernatant.

Compounds of the Examples were found to be antagonists of eotaxin mediated human eosinophil chemotaxis if the concentration response to eotaxin was shifted to the right of the control curve. Measuring the concentration of eotaxin required to give 50% chemotaxis in the presence or absence of compounds enables the apparent affinity of the compounds at CCR3 to be calculated.

CLAIMS

1. A compound of formula (I):



5

wherein:

T is C(O) or S(O)₂;

W is C(O) or S(O)₂;

X is CH₂, O or NH;

Y is CR⁵ or N;

10 R¹ is optionally substituted aryl or optionally substituted heterocyclyl;

R² is hydrogen or C₁₋₆ alkyl;

R³ is hydrogen or optionally substituted C₁₋₆ alkyl;

15 R⁴ is alkyl, optionally substituted aryl, optionally substituted aralkyl or optionally substituted heterocyclyl;

R⁵ is hydrogen or C₁₋₆ alkyl;

wherein the foregoing aryl and heterocyclyl moieties are optionally substituted by:

halogen, cyano, nitro, hydroxy, oxo, S(O)_pR²⁵, OC(O)NR⁶R⁷, NR⁸R⁹,

NR¹⁰C(O)R¹¹, NR¹²C(O)NR¹³R¹⁴, S(O)₂NR¹⁵R¹⁶, NR¹⁷S(O)₂R¹⁸, C(O)NR¹⁹R²⁰,

C(O)R²¹, CO₂R²², NR²³CO₂R²⁴, C₁₋₆ alkyl, CF₃, C₁₋₆ alkoxy(C₁₋₆)alkyl, C₁₋₆ alkoxy,

20 OCF₃, C₁₋₆ alkoxy(C₁₋₆)alcoxy, C₁₋₆ alkylthio, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀

cycloalkyl (itself optionally substituted by C₁₋₄ alkyl or oxo), methylenedioxy,

difluoromethylenedioxy, phenyl, phenyl(C₁₋₄)alkyl, phenoxy, phenylthio,

phenyl(C₁₋₄)alcoxy, heteroaryl, heteroaryl(C₁₋₄)alkyl, heteroaryloxy or

25 heteroaryl(C₁₋₄)alcoxy; wherein any of the immediately foregoing phenyl and

heteroaryl moieties are optionally substituted with halogen, hydroxy, nitro,

S(O)_q(C₁₋₄ alkyl), S(O)₂NH₂, cyano, C₁₋₄ alkyl, C₁₋₄ alkoxy, C(O)NH₂, C(O)NH(C₁₋₄ alkyl), CO₂H, CO₂(C₁₋₄ alkyl), NHC(O)(C₁₋₄ alkyl), NHS(O)₂(C₁₋₄ alkyl),

C(O)(C₁₋₄ alkyl), CF₃ or OCF₃;

p and q are, independently, 0, 1 or 2;

30 R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹², R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁹, R²⁰, R²¹, R²², and R²³ are,

independently, hydrogen, C₁₋₆ alkyl (optionally substituted by halogen, hydroxy or

C₃₋₁₀ cycloalkyl), CH₂(C₂₋₆ alkenyl), phenyl (itself optionally substituted by halogen, hydroxy, nitro, NH₂, NH(C₁₋₄ alkyl), N(C₁₋₄ alkyl)₂, S(O)₂(C₁₋₄ alkyl), S(O)₂NH₂, S(O)₂NH(C₁₋₄ alkyl), S(O)₂N(C₁₋₄ alkyl)₂, cyano, C₁₋₄ alkyl, C₁₋₄ alkoxy, C(O)NH₂, C(O)NH(C₁₋₄ alkyl), CO₂H, CO₂(C₁₋₄ alkyl), NHC(O)(C₁₋₄ alkyl), NHS(O)₂(C₁₋₄ alkyl), C(O)(C₁₋₄ alkyl), CF₃ or OCF₃) or heterocyclyl (itself optionally substituted by halogen, hydroxy, nitro, NH₂, NH(C₁₋₄ alkyl), N(C₁₋₄ alkyl)₂, S(O)₂(C₁₋₄ alkyl), S(O)₂NH₂, S(O)₂NH(C₁₋₄ alkyl), S(O)₂N(C₁₋₄ alkyl)₂, cyano, C₁₋₄ alkyl, C₁₋₄ alkoxy, C(O)NH₂, C(O)NH(C₁₋₄ alkyl), C(O)N(C₁₋₄ alkyl)₂, CO₂H, CO₂(C₁₋₄ alkyl), NHC(O)(C₁₋₄ alkyl), NHS(O)₂(C₁₋₄ alkyl), C(O)(C₁₋₄ alkyl), CF₃ or OCF₃);

alternatively NR⁶R⁷, NR⁸R⁹, NR¹³R¹⁴, NR¹⁵R¹⁶, NR¹⁹R²⁰ or N(C₁₋₄ alkyl)₂ may, independently, form a 4-7 membered heterocyclic ring, azetidine, pyrrolidine, piperidine, azepine, 1,4-morpholine or 1,4-piperazine, the latter optionally substituted by C₁₋₄alkyl on the distal nitrogen;

R²⁵, R¹⁸ and R²⁴ are, independently, C₁₋₆ alkyl (optionally substituted by halogen, hydroxy or C₃₋₁₀ cycloalkyl), CH₂(C₂₋₆ alkenyl), phenyl (itself optionally substituted by halogen, hydroxy, nitro, NH₂, NH(C₁₋₄ alkyl), N(C₁₋₄ alkyl)₂ (and these alkyl groups may join to form a ring as described for R⁶ and R⁷ above), S(O)₂(C₁₋₄ alkyl), S(O)₂NH₂, S(O)₂NH(C₁₋₄ alkyl), S(O)₂N(C₁₋₄ alkyl)₂ (and these alkyl groups may join to form a ring as described for R⁶ and R⁷ above), cyano, C₁₋₄ alkyl, C₁₋₄ alkoxy, C(O)NH₂, C(O)NH(C₁₋₄ alkyl), C(O)N(C₁₋₄ alkyl)₂ (and these alkyl groups may join to form a ring as described for R⁶ and R⁷ above), CO₂H, CO₂(C₁₋₄ alkyl), NHC(O)(C₁₋₄ alkyl), NHS(O)₂(C₁₋₄ alkyl), C(O)(C₁₋₄ alkyl), CF₃ or OCF₃) or heterocyclyl (itself optionally substituted by halogen, hydroxy, nitro, NH₂, NH(C₁₋₄ alkyl), N(C₁₋₄ alkyl)₂ (and these alkyl groups may join to form a ring as described for R⁶ and R⁷ above), S(O)₂(C₁₋₄ alkyl), S(O)₂NH₂, S(O)₂NH(C₁₋₄ alkyl), S(O)₂N(C₁₋₄ alkyl)₂ (and these alkyl groups may join to form a ring as described for R⁶ and R⁷ above), cyano, C₁₋₄ alkyl, C₁₋₄ alkoxy, C(O)NH₂, C(O)NH(C₁₋₄ alkyl), C(O)N(C₁₋₄ alkyl)₂ (and these alkyl groups may join to form a ring as described for R⁶ and R⁷ above), CO₂H, CO₂(C₁₋₄ alkyl), NHC(O)(C₁₋₄ alkyl), NHS(O)₂(C₁₋₄ alkyl), C(O)(C₁₋₄ alkyl), CF₃ or OCF₃);

or an N-oxide thereof; or a pharmaceutically acceptable salt thereof; or a solvate thereof.

2. A compound as claimed in claim 1 wherein X is O.

3. A compound as claimed in claim 1 or 2 wherein R¹ is phenyl substituted with one
5 or more of fluorine, chlorine, C₁₋₄ alkyl or C₁₋₄ alkoxy.

4. A compound as claimed in claim 1, 2 or 3 wherein one of T and W is C(O) and the
other is S(O)₂.

- 10 5. A compound as claimed in claim 1, 2, 3 or 4 wherein T is C(O).

6. A compound as claimed in claim 1, 2, 3, 4 or 5 wherein W is S(O)₂.


7. A compound as claimed in claim 1, 2, 3, 4, 5 or 6 wherein Y is N.

- 15 8. A compound as claimed in claim 1, 2, 3, 4, 5, 6 or 7 wherein R² is hydrogen or
methyl.

9. A compound as claimed in claim 1, 2, 3, 4, 5, 6, 7 or 8 wherein R³ is hydrogen.


- 20 10. A compound as claimed in claim 1, 2, 3, 4, 5, 6, 7, 8 or 9 wherein R⁴ is substituted
phenyl, the substituents being chosen from those provided in claim 1.

11. A process for preparing a compound formula (I) as claimed in claim 1 comprising:
25 a. when R³ is hydrogen, T is C(O) and Y is N, reacting a compound of formula
(II):




with an isocyanate of formula R⁴WN=C=O in the presence of a suitable solvent at a suitable temperature;

- 30 b. when T is C(O), W is S(O)₂ and Y is N, reacting a compound of formula (II)
with a compound of formula (XXII):




- c. when R³ is hydrogen, T is S(O)₂, W is C(O) and Y is N, reacting a compound of formula (IX):



5

with a compound of formula (II) in the presence of a suitable base, in a suitable solvent and at a suitable temperature;


- d. when R³ is hydrogen, T is S(O)₂, W is C(O) and Y is N, reacting a compound of formula (XVIII):



10

with an acyl halide R⁴COHal in the presence of a base, in a suitable solvent, at room temperature;


- e. when R³ is hydrogen, T is S(O)₂, W is C(O) and Y is N, reacting a compound of formula (XIX):



15


with an acyl halide R⁴COHal in the presence of a base, in a suitable solvent, for example at room temperature; followed by deprotection of the carbamate so formed;

- f. when T and W are both S(O)₂ and Y is N, reacting a compound of formula (X):




with a sulfonamide $R^4S(O)_2NHR^3$ in the presence of a base, in a suitable solvent;

- g. when T and W are both $S(O)_2$ and Y is N, reacting a compound of formula (XVIII) with a sulfonyl chloride R^4SO_2Cl in the presence of a base, in a suitable solvent;
- 5 h. when T is C(O), W is $S(O)_2$ and Y is CR^5 , can be prepared by firstly hydrolysing a compound of formula (XI):




10 wherein the ester is preferably a C_{1-6} alkyl group, and reacting the product so formed with $R^4S(O)_2NHR^3$ in the presence of an appropriate coupling agent, in a suitable solvent;

- i. when T and W are both C(O) and Y is CR^5 or N, can be prepared by heating a compound of formula (XIV):




15 in the presence of $R^4C(OR')_2N(CH_3)_2$ or $R^4C(OR')_3$, wherein R' is methyl or ethyl, or $(OR')_3$ is $(OCH_2)_3CCH_3$;

- j. when T is $S(O)_2$, W is C(O) and Y is CR^5 , coupling a compound of formula (XV):



20 to an acid R^4CO_2H in the presence of an appropriate coupling agent, in a suitable solvent;

- k. when T and W are both $S(O)_2$ and Y is CH, coupling a compound of formula (XV):



to a sulfonyl chloride $R^4S(O)_2Cl$ in the presence of a base and a solvent;

1. wherein R^3 is not hydrogen, can be prepared by alkylating a compound of formula (I) wherein R^3 is hydrogen, with a suitable alkylating agent in the presence of a suitable base in a suitable solvent; or,
- 5 m. Y is CR^5 and R^5 is not hydrogen, may be prepared from a compound of formula (I) where Y is CH by reaction of the dianion (R^3 is H) or monoanion (R^3 is alkyl) (formed with a suitable base) with an alkylating agent in a suitable solvent.

10

12. A pharmaceutical composition comprising a compound of the formula (I), or a pharmaceutically acceptable salt thereof or a solvate thereof, and a pharmaceutically acceptable adjuvant, diluent or carrier.

15

13. A compound of the formula (I) as claimed in claim 1, or a pharmaceutically acceptable salt thereof or a solvate thereof, for use in therapy.

20

14. The use of a compound of the formula (I) as claimed in claim 1, or a pharmaceutically acceptable salt thereof or a solvate thereof, in the manufacture of a medicament for use in therapy.

25

15. A method of treating a chemokine mediated disease state in a mammal suffering from, or at risk of, said disease, which comprises administering to a mammal in need of such treatment a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, solvate or solvate of a salt thereof, as claimed in claim 1.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 02/01311

A. CLASSIFICATION OF SUBJECT MATTER

**IPC7: C07D 401/04, C07D 401/14, C07D 409/14, C07D 417/14, C07D 211/06,
A61K 31/445, A61P 37/00, A61P 11/06, A61P 31/16**

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: C07D, A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-INTERNAL, WPI DATA, PAJ, CHEM. ABS DATA

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 0177101 A1 (ASTRAZENECA AB), 18 October 2001 (18.10.01) --	1-15
P,X	WO 0192227 A1 (ASTRAZENECA AB), 6 December 2001 (06.12.01) --	1-15
P,X	WO 0220484 A1 (ASTRAZENECA AB), 14 March 2002 (14.03.02) --	1-15
P,X	US 6387930 B1 (BAHIGE M. BAROUDY ET AL), 14 May 2002 (14.05.02) --	1-15

 Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier application or patent but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

21 October 2002

Date of mailing of the international search report

23-10-2002Name and mailing address of the ISA/
Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. + 46 8 666 02 86Authorized officer
Gerd Strandell/EÖ
Telephone No. + 46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 02/01311

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 0066559 A1 (SCHERING CORPORATION), 9 November 2000 (09.11.00) --	1-15
X	WO 9724324 A1 (JANSSEN PHARMACEUTICA N.V.), 10 July 1997 (10.07.97) --	1-15
X	WO 9805292 A2 (SCHERING CORPORATION), 12 February 1998 (12.02.98) --	1-15
X	WO 9806697 A1 (SCHERING CORPORATION), 19 February 1998 (19.02.98) -----	1-15

INTERNATIONAL SEARCH REPORTInternational application No.
PCT/SE02/01311**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: **15**
because they relate to subject matter not required to be searched by this Authority, namely:
see next sheet
2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORTInternational application No.
PCT/SE02/01311

Claim 15 relates to a method of treatment of the human or animal body by surgery or by therapy/a diagnostic method practised on the human or animal body/Rule 39.1(iv). Nevertheless, a search has been executed for this claim. The search has been based on the alleged effects of the compound/composition.

INTERNATIONAL SEARCH REPORT

Information on patent family members

30/09/02

International application No.

PCT/SE 02/01311

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 0177101 A1	18/10/01	AU 4699701 A GB 0008626 D US 2002077337 A GB 0019111 D SE 0003664 D		23/10/01 00/00/00 20/06/02 00/00/00 00/00/00
WO 0192227 A1	06/12/01	AU 6288601 A GB 0013060 D		11/12/01 00/00/00
WO 0220484 A1	14/03/02	AU 8458401 A GB 0021670 D		22/03/02 00/00/00
US 6387930 B1	14/05/02	NONE		
WO 0066559 A1	09/11/00	AU 4501000 A BR 0010607 A CN 1349504 T CZ 20013941 A EP 1175402 A NO 20015365 A TR 200103213 T		17/11/00 13/02/02 15/05/02 17/04/02 30/01/02 03/01/02 00/00/00
WO 9724324 A1	10/07/97	AT 206397 T AU 707037 B AU 1308497 A BR 9612334 A CA 2238818 A CZ 9801864 A DE 69615700 D,T DK 855999 T EP 0855999 A,B SE 0855999 T3 ES 2164939 T HU 9904125 A IL 124640 D JP 2000502690 T NO 310913 B NO 982404 A NZ 325843 A PL 327441 A PT 855999 T SI 855999 T SK 83198 A TR 9801211 T US 6169097 B US 6346540 B ZA 9610885 A		15/10/01 01/07/99 28/07/97 02/03/99 10/07/97 16/12/98 05/09/02 21/01/02 05/08/98 01/03/02 28/06/00 00/00/00 07/03/00 17/09/01 19/08/98 28/05/99 07/12/98 28/03/02 00/00/00 11/02/99 00/00/00 02/01/01 12/02/02 23/06/98

INTERNATIONAL SEARCH REPORT

Information on patent family members

30/09/02

International application No.

PCT/SE 02/01311

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9805292 A2	12/02/98	AU	724001 B	07/09/00
		AU	3899997 A	25/02/98
		BR	9711119 A	23/11/99
		CN	1084743 B	15/05/02
		CN	1232462 A	20/10/99
		CZ	9900366 A	16/06/99
		EP	0938483 A	01/09/99
		HU	9902827 A	28/08/00
		IL	128409 D	00/00/00
		JP	2000501117 T	02/02/00
		NO	990551 A	07/04/99
		NZ	333801 A	28/04/00
		PL	331534 A	19/07/99
		SK	15599 A	13/03/00
		TR	9900255 T	00/00/00
		US	5889006 A	30/03/99
		US	6043255 A	28/03/00
		ZA	9707011 A	06/02/98
<hr/>				
WO 9806697 A1	19/02/98	AU	732096 B	12/04/01
		AU	3973297 A	06/03/98
		BR	9711061 A	17/08/99
		CN	1232453 A	20/10/99
		CZ	9900433 A	14/07/99
		EP	0922029 A	16/06/99
		HU	9904363 A	28/11/00
		IL	128524 D	00/00/00
		JP	2000500786 T	25/01/00
		NO	990671 A	15/04/99
		NZ	334017 A	28/04/00
		PL	331536 A	19/07/99
		SK	20199 A	13/03/00
		TR	9900314 T	00/00/00
<hr/>				